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ABSTRACT 
 
Glycine, a lipophilic non-essential amino acid biosynthesized from L-serine, L-alanine and 
L-threonine, plays a role in the biosynthesis of proteins, nucleotides, and glutathione. It is a 
neurotransmitter in the central nervous system and acts as a co-agonist at the N-methyl-D 
aspartate (NMDA) receptor. Oral administration of glycine is helpful in the management of 
schizophrenia. While long-term oral treatment with glycine is considered to exert a cardio-
vascular protective role by overcoming endothelial dysfunction and oxidative stress, there 
are no systematic studies examining the cardiovascular effects of glycine. Recently, we 
showed that the precursor/metabolite of glycine, L-serine, evoked endothelium-dependent 
vasodilatation in rat mesenteric arterioles. Acute intravenous administration of L-serine 
produced a rapid, dose-dependent fall in blood pressure (BP) in both normotensive and 
hypertensive rats. These responses were abolished in the combined presence of the Ca2+ 
activated small and intermediate conductance K+ channel inhibitors, apamin and Tram-
34/charybdotoxin. In contrast, intravenous administration of glycine evoked a fall in BP in 
normotensive Wistar-Kyoto (WKY) rats and an elevation of BP in spontaneously 
hypertensive rats (SHR), and in WKY rats subjected to chronic nitric oxide (NO) synthase 
(NOS) inhibition by oral treatment with NOS inhibitor, L-NAME (NG-nitro-L-arginine-
methylester). Therefore, in vivo and in vitro studies were designed to address the 
mechanisms that contribute to the opposite effects of glycine in normotensive vs. 
hypertensive rats.  
  
Experiments were performed using 14 weeks old male WKY, chronic L-NAME treated 
WKY and SHR strains. In vivo studies involved examination of changes in systemic 
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hemodynamic parameters such as mean arterial pressure (MAP), heart rate (HR), total 
peripheral resistance (TPR) and cardiac output (CO) as well as regional hemodynamic 
parameters of changes in blood flow and vascular resistance in major organs/tissues 
following acute intravenous administration of glycine using fluorescent microsphere 
distribution technique. Parallel complementary in vitro studies were conducted to examine 
the effects of glycine on changes in basal tone and phenylephrine (PE) constricted tone in 
aortic rings with endothelium-intact and endothelium-denuded states after isolation from 
WKY and SHR strains. All these studies were conducted in the presence and absence of 
two NMDA antagonists, MK-801 and memantine. 
 
In normotensive WKY rats, glycine (1 mmol/L) administration decreased MAP (P<0.01), 
TPR (P<0.05) while it increased CO (P<0.01) and blood flow to brain (215%), kidney 
(190%) and heart (160%). In SHR and L-NAME treated WKY rats, glycine administration 
elevated MAP and TPR but reduced CO (P<0.01) and blood flow to brain, kidney and 
heart. These effects were abolished in animals pretreated with either MK-801 or 
memantine. These data are consistent with the likely expression of vascular NMDA 
receptors activated by glycine in brain and kidney.  Glycine (0.5-3.0 mmol/L) per se 
increased basal tone (Emax1.4g) in aortic rings from all rats and it was absent following 
incubation with NMDA antagonist(s). The concentration-dependent vasodilatation 
(Imax43%) evoked by glycine in PE-constricted rings with intact endothelium of WKY rats 
was attenuated by either MK-801 or L-NAME. Such vasodilator responses to glycine could 
be abolished by pretreatment with either NMDA antagonist or L-NAME. In contrast, in PE-
constricted rings of SHR strain, addition of glycine enhanced the tone and this was 
abolished in the presence of NMDA antagonist, MK-801.  
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Taken together, these data suggest that NMDA receptors, likely present on both 
endothelium and vascular smooth muscle cells, predominantly in brain, kidney and 
coronary vascular beds as well as the conduit vessel, aorta, could contribute to the systemic 
and regional hemodynmic effects of glycine. In normotensive WKY rats, addition of 
glycine promotes endothelium/NO-dependent vasodilatation subsequent to Ca2+ 
mobilization evoked following endothelial NMDA receptor activation by glycine. Thus, 
glycine-induced dose-dependent, reversible fall in MAP and TPR in normotensive WKY 
rats is likely associated with NO-dependent/endothelium-mediated vasodilatation.  
However, in hypertensive rat models such as in the SHR model with endothelial 
dysfunction and reduced NO bioavailability or in chronic L-NAME treated rats, glycine 
administration promotes vascular NMDA receptor activation leading to enhanced vascular 
tone resulting in increased TPR and MAP. 
 
These observations are important and critical in terms of considering glycine as a possible 
antihypertensive agent as this was proposed by several earlier reports that did not explore 
the direct vascular effects of glycine in hypertensive animal models.  
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         CHAPTER 1 
         INTRODUCTION 
 
1.1. Hypertension as a global problem 
 
 High blood pressure (BP) also called hypertension, is a clinical condition with 
elevated arterial pressure (Kannel, 1990). Precisely BP is the force of pressure exerted by 
blood circulation against the arterial wall and is expressed in ratio of upper systolic and 
lower diastolic pressure in mmHg.  Systolic pressure is the pressure under which the heart 
contracts and pumps out oxygenated blood to the system for metabolic need, whereas 
diastolic pressure is the pressure under which the heart relaxes and fills with blood. In 
hypertensive patients, the arterial wall becomes stiff due to lack of elasticity and the 
subsequent decrease in compliance increases resistance to blood flow in arteries. In this 
condition, the heart has to pump harder in order to push the blood through the small 
arteries. Increased BP eventually makes the heart weak and this leads to left ventricular 
hypertrophy and heart failure (Kannel, 1990 and 1996). This increase in BP is directly 
proportional to the resistance in arteries and inversely linked to lumen diameter and 
arterial wall thickening. Development of cardiovascular disease (CVD) state is related 
and resultant of high BP (Kannel, 1996). Sustained high BP increases the chances of 
cerebral stroke, due to inadequate blood flow and rupture of small arterioles in the brain 
leading to stroke (Levy et al., 1996).  
      
Physiologically, BP is considered to be normal when the systolic and diastolic pressure 
value is 120/80 mmHg. However, several known and unknown factors are associated 
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with the elevation of these two values. According to the seventh report of Joint National 
Committee (JNC VII), systolic pressure ≥140 and diastolic pressure >90 mmHg is 
considered to be hypertension (Carretero et al., 2000; Chobanian et al., 2003). It has been 
reported that renal disease and diabetes contribute to high BP (Chobanian et al., 2003). A 
hypertensive state is established when pressure in the arteries remains high for an 
extended period of time. High BP is usually seen in the middle aged group and elderly 
people (Morrison et al., 1991). However, there are instances of some youngsters who 
develop high BP (Mouria et al., 2004).  Once it develops, it has a tendency to become 
resistant to treatment and stays throughout. Life style changes, therapeutical intervention 
and regular pressure monitoring are required in most cases. Since the heart has to work 
under high pressure continuously, it eventually fails and this leads to target organ damage 
(Gregory et al., 2000). If hypertension is left untreated, it can lead to stroke, coronary 
heart disease and renal failure (Rossi et al., 1995). High BP affects the pumping ability of 
the heart, which in turn contribute adversely to the entire circulatory system. So it is 
essential and important to treat hypertension at its early onset. 
 
Hypertension has become a serious global health problem and it is now recognized as one 
of the most common contributing factors to all forms of CVD which accounts for 20-50% 
of death (Castelli et al., 1984; Rosenfeld et al., 1995; World Health Organization (WHO) 
1996).  Although the exact cause of essential hypertension is still unknown, some of the 
major factors which permissively contribute to hypertension are diabetes, stress, obesity, 
lack of physical activity, smoking, high blood cholesterol, excess alcohol consumption, 
excess salt in diet (Elley et al., 2002; Klaus et al., 2009). Although there is a continuing 
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improvement in appropriate diagnosis and treatment of CVD, the most common cause for 
premature mortality and disability in adults is due to coronary artery disease and stroke 
(Hatmi et al., 2007; Coca et al., 2008). Due to an increasing risk of CVD all over the 
world irrespective of treatment, global risk assessment now has become very important 
next to therapy. Persons with hypertension are usually associated with dyslipidemia, 
impaired glucose tolerance and abdominal obesity (Manreque et al., 2010). Elevated 
blood pressure for all age groups is a major risk factor for atherosclerosis, coronary heart 
disease, heart failure, brain and myocardial infarction.  Epidemiological studies have 
shown that factors associated with urbanization, environmental and geographical changes 
are related or correlated to the manifestation of hypertension and related cardiovascular 
diseases (Van et al., 2000). In most cases, pre or mild hypertension remains 
asymptomatic for long period of time and comes only under medical supervision when it 
manifests with severe complications. It has been reported that the rate of morbidity and 
mortality in patients with mild hypertension are such that a person aged 35 years with BP 
140-150/90-100 mmHg without treatment, easily shortens life span by 15 years 
(Pickering et al., 1974). In such cases, treatment with antihypertensive drugs has shown 
that the overall incidence of complications can be significantly reduced and the death rate 
could be correspondingly minimized. Epidemiological studies show that in spite of a 
downward trend in mortality rate, hypertension still is the major cause of death in the 
western hemisphere (Waller et al., 1983; Stamler, 1985; Uemura et al., 1985; Tuomilehto 
et al., 1986; Ghannem et al., 1996). A recent report suggested that approximately one 
billion people worldwide have high BP, and by the end of 2025 this  figure is expected to 
increase to one and half billion  affecting one in three adults over the age of 20 (Kearney 
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et al., 2005). Globally around eighteen million deaths occur due to CVD, most of them 
are either suffering from diabetes or hypertension or both (Parvez et al., 2007). According 
to a recent assessment by the WHO, CVD stands as the number one cause of death 
globally. In 2004, approximately seventeen million people died from CVD, which 
represents 29% of the total global deaths. Seven million out of seventeen million deaths 
were due to coronary heart disease and six million were due to stroke (WHO, 2009). In 
developing and undeveloped countries 82% deaths are due to CVD. In the next two 
decades nearly twenty four million people will die mainly from stroke and heart related 
diseases (WHO, 2009). 
 
North American prespective: However, the current survey demonstarted that there is an 
increasing trend in the prevalence of hypertension and CVD despite treatment (Kazuko, 
2010). A report by National Health and Nutrition Examination Survey (NHANES) has 
found that hypertension, obesity and diabetes have increased in the United States in the 
past decade (Kazuko, 2010). Hypertension has become the leading cause for all forms of 
CVD in North America (Heart and Stroke Foundation of Canada, 2003). Hypertension is 
the leading global risk factor for mortality, and related heart and kidney diseases 
(Statistics Canada, 2005; Stone, 2010).  According to a recent statistical survey report 
approximately five million adults, who accounts for nearly one fifth of the total Canadian 
population are suffering from hypertension (Stone, 2010). Apart from this population 
diagnosed many people remain unaware of their condition/undiagnosed due to lack of 
regular check up. Although 80% of the hypertensive population is under antihypertensive 
therapy, BP is being controlled only in 66% of that population (Stone, 2010). This study 
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shows that a small percentage of the population is resistant to current antihypertensive 
medications. Perhaps further diagnosis and more aggressive dose regimen would bring 
down the prevalence. BP still remains high in about one third of the hypertensive adults 
irrespective of antihypertensive therapy and regular BP monitoring. We need more 
research and studies to ensure total reduction of this fatal disease. 
  
Canadian prespective: A recent Canadian Broadcasting Corporation (CBC) news bulletin 
highlighted that high BP is becoming a national crisis in younger Canadians (<20 years) 
due to increased rate of obesity, diabetes and physical inactivity (CBC News, 2010).  
According to the Heart and Stroke Foundation of Canada, there are more than 250,000 
young Canadians with high BP (CBC News, 2010).  
 
Saskatchewan Scenario: Another survey report described that CVD is the major cause of 
death in the senior population of Saskatchewan, which accounts for 26.2% of total death 
per year (A Health Profile of Saskatchewan Seniors, 2003). Taking all these issues into 
consideration, it is worthy and important to think and move forward in a constructive way 
to fight against high BP which is the key cause for all forms of CVD. Our ultimate goal is 
to live a disease free life; it is only possible if we are aware of ourselves. Awareness, and 
life style changes include physical exercise, dietary changes, weight loss and appropriate 
treatment with regular check up which would help us to achieve this desired goal.  
 
1.1.1. Types of hypertension  
Currently hypertension is classified into the three following categories:   
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1.1.1.1. Prehypertension 
Previously, it was considered that systolic and diastolic pressure, which varies 
between 120-139 and 80-89 mmHg, is high normal. But this concept has been changed 
overtime. Recently the new guidelines provided by national Heart, Lungs and Blood 
Institute (NHLBI) which reclassified the upper systolic and lower diastolic pressure range 
for better monitoring and prevention of early onset of hypertension. In this new 
classification, they added a condition called prehypertension, along with primary and 
secondary hypertension. According to this new guideline, prehypertension defines 
systolic and diastolic pressure between 121-139 and 81-89 mmHg. This might be the 
early symptoms for and could lead to well established hypertension. Usually people 
diagnosed with prehypertension are advised to incorporate life style changes and are 
encouraged to check up BP at least once a year.  People who fall under this 
prehypertensive category are normally prescribed non-pharmacological treatment that 
includes physical activity, diet control and minimize direct salt intake (NHLBI). 
According to the data provided by the NHAES III, since 1999-2000 approximately 31% 
of adult Americans were diagnosed as prehypertensive (prehypertension and borderline 
hypertension, 2007). The prevalence was more in male which is 39% compared to female 
23% (Hasia et al., 2007). Based on a recent survey report by Durham Regional Hospital 
nearly 45 million American people fall under this category (Durham regional hospital, 
2004). Table 1 describes the recommended blood pressure levels suggested by the 
American Heart Association. 
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BP Category Systolic (mmHg)  Diastolic (mmHg) 
Normal         120 and             80 
Prehypertension       121 -139 or           81- 89 
High-Stage I       140 -159 or           90 - 99 
High-Stage II        ≥ 160             ≥ 100 
 
Table 1. Classification of recommended blood pressure levels, American Heart 
Association. 2007. 
 
Prehypertension is asymptomatic phase and has the potential to increase the risk of 
primary hypertension which subsequently could contribute to the development of CVD 
(Vanas et al., 2001; Qureshi et al., 2005). A person with  prehypertension is three times 
more likely to have heart attack and 1.7 times to have heart related diseases compared to 
a normal individual (American Heart Association, 2005). So it has been suggested that 
prehypertension is the early phase of an impending well established hypertension 
(NHLBI report). Therfore it is very important to diagnose periodically and control 
prehypertension accordingly to overcome the risk of hypertension. 
 
1.1.1.2. Essential or primary hypertension 
Hypertension with no apparent cause is called essential or primary hypertension 
which accounts for 95% of the total hypertensive population (Carretero et al., 2000; 
Oparil et al., 2003; Hall et al., 2006; Hypertension: eMedicine Nephrology. 2009). Often 
essential or primary hypertension is also termed clinically as idiopathic hypertension. 
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Essential hypertension is a silent killer because it goes unnoticed without any visible 
complications initially. If not treated, at a later stage it contributes to cardiovascular 
complications like stroke, angina and heart failure. People with primary hypertension 
usually seen with combined elevation of both systolic and diastolic pressure. But in some 
cases mostly in elderly patients, only systolic pressure increases and is called as isolated 
systolic hypertension (Carretero et al., 2000). The specific cause for the combined 
systolic and diastolic or isolated systolic hypertension is not known. Although there is no 
specific reason mentioned yet how primary hypertension develops, several underlying 
factors may presumably be associated with it. A brief overview on this topic is provided 
below.  
 
1.1.1.2.1. Factors associated with essential hypertension 
Although there is no definite cause for the pathophysiological development of 
primary hypertension, some studies mention that genetic and environmental factors may 
contribute to primary hypertension (Morton et al., 1962; Avolio, 1995; Barlasinna et al., 
1997; Rostand, 2003; Franks, 2008). Many genes are thought to be involved and work as 
a network system to bring about phenotypic changes, which are inherited from one 
generation to the other (Melander, 2001). The defective phenotypic changes are thought 
to be  associated with  abnormal cell membrane ion transport (Na+, K+ and Ca2+ channels 
present  on the cell membrane), Na+ excretion in the kidneys and sympathetic activation 
to promote the release of neurogenic hormones (Vikrant et al., 2001; Delpir et al., 2002; 
Hall, 2003; Ranke, 2003; Rosendroff, 2006; Eberhard et al., 2009). Some of the factors 
likely are associated with high BP are high dietary salt intake, smoking, heavy alcohol 
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consumption, ethnicity, impaired glucose tolerance, genetic disposition (family history of 
hypertension), age and gender. High dietary Na+ intake has long been shown as a 
contributing factor in developing hypertension (Wyss, 2006; Theresa et al., 2006; Cook et 
al., 2007). However  recent studies have shown that individuals taking low K+, Mg2+ and 
Ca2+ in their diet are also likely to develop hypertension (Northcott et al., 2004; Nijenhuis 
et al., 2005). 
 
To explain the onset of primary hypertension is not very easy but several hypotheses have 
been proposed to elucidate the issue. Briefly they are as follows: 
 
(i) Malfunction in body’s autoregulatory system. 
(ii) Over stimulation of sympathetic nerve fibers supplying to heart and blood vessels 
(iii) Inappropriate diuresis and natriuresis by the kidneys 
(iv) Increase in blood volume and malfunction of Na+/K+ transport, which is regulated by 
hormones across the cell membrane of blood vessels and kidneys. 
 
There are two important hypothesis proposed for the development of primary 
hypertension, the hemodynamic hypothesis and the neuronal hypothesis (Feig et al., 
2003; De Luca et al., 2007). 
 
The hemodynamic hypothesis is closely associated with the above mentioned hypothesis, 
whereas the neuronal hypothesis is specifically related to body’s fluid volume and its 
regulation (Fetnat et al., 1997; Vasquez et al., 1997; Schrier et al., 1998; Feig et al., 2003; 
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De Luca et al., 2007; Spaan et al., 2009). Precisely fluid and electrolyte balance is 
interrelated. So we could safely say that both hemodynamic and neuronal hypotheses are 
closely related to each other and may be playing a role in developing hypertension. 
 
1.1.1.3. Secondary hypertension 
Hypertension with known cause is called as secondary hypertension. It is less 
common and accounts for only 5-10% of the total hypertensive population (Onusko et al., 
2003). It is usually associated with other disease conditions like chronic renal disease, 
renal artery stenosis, pheochromocytoma, hypothyroidism, hyperthyroidism, chronic liver 
cirrhosis, hyperaldosteronism, iatrogenic or drug induced such as following long term 
corticosteroid therapy, pregnancy induced, sleep apnea and birth defect (Saken et al., 
1979; Walker et al., 1994; O'Rorke et al., 2001; Wolk et al., 2003; Bradley, 2003; Seeley 
et al., 2007; Hulisz et al., 2008; Klabunde, 2009; Tanous et.al., 2009; Fallo et al., 2010).  
 
1.2. Regulation of blood pressure 
BP is regulated and controlled over a narrow range. It depends on the lumen size 
of the arterioles which contributes to change in the resistance of the vasculature. 
Basically BP is the function of three different properties called capacity, compliance and 
elasticity of the vascular compartments (Medical physiology, A.C. Guyton). Systems that 
regulate BP include nervous system, renin angiotensin-aldosterone system (RAAS) and 
humoral system. The major determinants of BP regulation are blood volume, cardiac 
output (CO) and total peripheral resistance (TPR). Blood volume in the vascular 
compartment depends largely on the rate at which blood flows in to and out of it. On the 
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other hand CO is the blood flow rate into the major arteries from the pumping action of 
the heart and determined mostly by venous return. Over a period of time CO and venous 
return has to be equal. They together represent the total blood flow in the circulatory 
system. Again venous return is detrmined by TPR and the pressure gradient for its return 
which depends on mean circulatory filling pressure which represents the capacitance 
function of the circulation. TPR represents the combined resistance in the circulation 
which is directly proportional to the rate at which blood leaves the arteries and arterioles. 
The relationship between BP, CO and TPR can be represented as BP=CO*TPR. Blood 
flow and resistance are two important determinants of the TPR. The fundamental 
principle of blood flow through different vascular beds should be equal to the difference 
between the arterial and venous pressure of vascular beds and this should be divided by 
resistance which determines the rate of flow. Resistance is always inversely proportional 
to the fourth power of the radius of the lumen of the vessel. Based on the above, the 
formula for the measurement of flow can be represented for calculation purposes as 
follows:  
F=Pa-Pv/R or ∆ BF/r 4. Where F = flow, Pa = arterial pressure, Pv = venous pressure, R = 
resistance, BF = blood flow, r = radius. 
 
These determinants are continuously modified in an integrated and coordinated fashion 
by neural, renal and chemical control systems to maintain physiological homeostasis. 
This adjustment, controls efficiently and properly the entire perfusion system. But in case 
of pathophysiological conditions, these determinants are modified in an irregular manner 
which leads to cardiovascular complications. The entire BP regulatory system is 
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primarily controlled by two different mechanisms. The details of control mechanisms for 
BP regulation are described below. 
 
1.2.1. Remote control system  
The remote control system consists of parasympathetic nervous system (PNS), 
sympathetic nervous system (SNS) and the humoral system. They are important in short 
term control of BP by regulating BP and blood volume. 
 
1.2.1.1. Nervous system 
 Blood vessels are primarily innervated by SNS where as heart is innervated by 
PNS and SNS. 
 
 1.2.1.1.1. Neural control 
The baroreceptor reflex arch is an important component of neural control (Mc 
Corry, 2007). The second to second BP monitoring is controlled by arterial and cardiac 
baroreceptor reflex action in an integrated manner. These baroreceptors respond to 
vascular stretch. These actions are controlled by sending signals through afferent fibres 
from arterial and cardiac baroreceptors which transmits the signals through cranial nerves 
(IX and X) to nucleus of the tractus solitarius. The mediator is an excitatory 
neurotransmitter, glutamate, which activates caudal ventrolateral medulla (CVLM) in 
turn sends inhibitory fibres to rostral ventrolateral medulla (RVLM), the primary 
regulator of sympathetic nervous system.  By inhibiting RVLM which sends excitatory 
glutaminergic fibers to sympathetic preganglionic neurons located in the spinal cord, this 
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inhibits sympathetic activation in response to increase in BP (Patron et al., 2009). This 
process controls BP dynamically by neural communication associated with baroreceptors 
which responds to the changing diameter of the blood vessels (Mc Corry, 2007, Patron et 
al., 2009). Neural control of BP regulation is a very complex process and occurs mostly 
by the reflex arcs, and to some extent involves chemoreceptors and higher brain centers 
(Zanzinzer., 1999, Dampney et al., 2005). The pathway of neural reflex arc and its 
response is somewhat integrated with vasomotor fibers, vasomotor center and 
pressoreceptors (Bernthal et al., 1944; Scherre, 1962; Miyakayo, 1988).  
 
1.2.1.1.1.1. Vasomotor fibers 
Vasomotor fibers are efferent nerve fibers from SNS innervating the membrane of 
vascular smooth muscle cells (VSMC) of arteries (Bonn, 1990). The vasomotor fibers 
release norepinephrine (NE) which is a potent vasoconstrictor (Westfall et al., 1985). 
Some of the vasomotor fibers also innervate the skeletal muscle and releases 
acetylcholine (ACh) which are known as vasodilator fibers (Welse et al., 1997).  They 
play an important role locally in the blood flow to muscle during exercise (Blair et al., 
1961; Joyner et al., 2007). However they do not have any control in regulating overall 
systemic circulation compared to vasomotor fibers that releases NE in VSMC of arteries 
(Kirkman et al., 2004; Thomas et al., 2004). 
 
 
1.2.1.1.1.2. Vasomotor center 
The vasomotor system controls BP and consists of a tangle of sympathetic nerve 
fibers located in the medulla (Lindsley, 1956; Engel et al., 1945; Cusingh et al., 1901; 
Shawn et al., 2004). Impulses are conducted from the vasomotor center through the 
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vasomotor fibers which are innervated to the arteries (Sergeeva, 1957). This impulse 
conduction depolarizes VSMC and results in an arteriolar contraction which we often call 
vasomotor tone. With the increase in impulse conduction, arteriolar contraction increases 
which contributes to the elevation of systemic BP (Hungerford et al., 2000; Welsh, 1994). 
With the subsequent reduction in firing there is a decrease in impulse conduction which 
decreases arteriolar contraction and we see a reduction in systemic BP (Gavaghan, 1998).  
 
 
1.2.1.1.1.3. Pressoreceptors 
Pressoreceptors are found in all large arteries of the thorax, neck, carotid and 
aortic sinuses, which can detect the changes in the arterial pressure (Jeweet, 1964; Scher, 
1977). With the increase of arterial pressure these receptors stretch and send a fast 
impulse to the vasomotor center (Rodbard et al., 1951; Miyakawa, 1988; Gavaghan, 
1998). Once the impulse reaches the vasomotor center, it reduces the impulse through the 
vasomotor fibers and brings down the BP by vasodilatation (Wang, 1953). It has been 
reported that afferent impulses from the pressoreceptors modulate the cardiac inhibitory 
center which decreases HR and cardiac contractility (Rothe et al., 1990). This in turn 
decreases mean arterial pressure (MAP) and activates lowpressure receptors, which 
ultimately disinhibit the RVLM and stimulate preganglionic sympathetic nerve fibers to 
release NE and constricts blood vessels with subsequent increase in BP to physiological 
level (Ludbrook J, 1983). The pressoreceptors are good at short term changes in BP 
(Ludbrook J, 1983; Collins R, 1990). However, there is no direct evidence as such for 
their role in regulating BP in chronic hypertensive state since threshold BP level for firing 
often changes or adapted in this disease condition (Yang et al., 1991). 
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1.2.1.1.1.4. Chemoreceptors 
These receptors are mainly found in the aortic arch and the large arteries of neck 
(Timmer et al., 2003, Ishii et al., 1985). Although they contribute to the BP, their role is 
important during respiration (Ishii et al., 1986, Benchetrit et al., 1997). Primarily they 
sense a decrease in oxygen content and increase in hydrogen ion level in blood. By doing 
so they generate and send an impulse to the vasomotor center through the vasomotor 
fibers resulting an increase in vasoconstriction, led to increases in BP (Suleman et al., 
2008).  
 
1.2.1.1.1.5. Higher brain centers 
Higher brain centers include hypothalamus and cortex (Hilton, 1983). They play a 
role in the regulation of BP during a situation like fight or flight by relaying the 
information to the medullary center (Hilton, 1983; Green et al., 2008).  Since reflexes that 
control BP are present in the medullary center, after receiving the information from the 
higher brain centers, it acts accordingly and increases BP all of a sudden by releasing NE 
(Folkow, 1960). 
 
1.2.1.2. Humoral system 
The humoral system controls BP mainly by chemical control and renal regulation.  
 
1.2.1.2.1. Chemical controls 
There are some endogenously formed chemicals such as epinephrine, NE, 
arginine vasopressin and atrial natriuretic peptide (ANP), which can alter BP by acting 
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directly on vascular smooth muscle cell (VSMC) or on the vasomotor center (Flynn. 
1996). Chemical control is important in short term regulation and maintenance of BP 
(Quan et al., 2006, Lohmeire, 2003). 
 
1.2.1.2.1.1. Adrenal medulla hormones 
During certain conditions like excitement or stress, cells in the adrenal medulla 
synthesize and secrete two catecholamines into circulation; they are epinephrine and NE 
(Jarry et al., 1995). After being released into the blood, they bind to the adrenergic 
receptors present on the target cells and exert their effect which is commonly called as 
fight and flight response (Vingerhoetes, 2002). By acting directly on heart, it increases 
the cardiac contractility, conduction velocity, automaticity and CO whereas it increases 
vascular contractility and periphearal vascular resistance by acting on blood vessels. Both 
epinephrine and NE increase BP by acting directly on cardiac tissue as well as the 
peripheral vasculature (Herrmann, 1982 and Buckwalter et al., 1997). 
 
1.2.1.2.1.2. Atrial natriuretic peptide 
ANP is a vasoactive substance released from the atria of the heart in response to 
high BP due to volume overload (Flynn, 1996).  It is a powerful vasodilator responsible 
for reduction in BP by reducing blood volume (Flynn., 1996, de Los Angeles et al., 
2000). It has potential to reduce cerebrospinal fluid formation and has a generalized 
vasodilatory effect in brain (Lida et al., 2001). Secretion and release of ANP is an 
autonomic function and it contributes to the short term BP control (Portaluppi et al., 
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1993). It has a short half-life due to the buffering effect of its clearance receptor subtype 
C (Yohio et al., 2003; Frajewicki et al., 1997). 
 
1.3.1.2.1.3. Antidiuretic hormone (ADH) 
 Arginine vasopressin (AVP) is an antidiuretic peptide hormone synthesized in the 
hypothalamus of most mammals. It is then transported to the posterior pituitary via axons 
and released following appropriate stimuli (Schrier et al., 1980). AVP exerts its effect 
primarily by acting on its receptors, V1 and V2 (Kjaer, 1994; Zingg., 1996; Caldwell et 
al., 2006; Aoyagi et al., 2009). These receptors are present in blood vessels and kidney. 
The major function of AVP is to regulate extracellular fluid volume by controlling renal 
handling of water (Forsling et al., 1988). AVP acts on V2 receptors located on renal 
collecting ducts to increase water permeability and this mechanism is cAMP-dependent 
(Fernandes et al., 2002; Schrier et al., 2006). This subsequently leads to a decreased urine 
formation. This decrease in urine formation increases blood volume, CO and arterial 
pressure. In VSMC, AVP binds to its V1 receptors causes vasoconstriction via IP3 signal 
transduction pathway (Robert et al., 2005).  This in turn increases arterial pressure and 
results in a compensatory increase in peripheral vascular resistance.  However, the main 
stimulus for AVP release is ‘hypovolemic shock’. 
 
1.2.1.2.1.4. Ouabain like factor and dihydroouabain like factor 
Ouabain like factors (OLF) and dihydroouabain like factor (DH-OLF) are 
endogenous cardinolides, synthesized by adrenal cortex and serves as a circulating 
hormone in the blood (El-Masri et al., 2002; Boulanger et al., 1993; Hamlyn et al., 1991). 
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They resemble digitalis glycoside in their structure and function (Goto et al., 1998). Like 
digitalis glycoside, OLF and DH-OLF inhibit Na+/K+ ATPase in the cell membrane. By 
inhibiting Na+/K+ ATPase, it increases intracellular Na+ level and increases vascular tone 
(Goto et al., 1998). They induce natriuresis, thereby reducing plasma osmolality, and 
blood volume and BP in conditions of essential hypertension, but are also involved in the 
pathogenesis of essential hypertension (Bloch et al., 1988; Blaustein et al., 1993). 
 
1.2.1.2.2. Renal regulation 
The renal regulation plays an important role in long term BP control. It can be 
classified into two different but interrelated systems, the renin angiotensin and 
aldosterone system (RAAS) and the kallikrein kinin system (Vecsei et al., 1978; 
Matsuda., 1984; Nolly et al., 1992; Yayama et al., 2000).  
 
1.2.1.2.2.1. Renin angiotensin and aldosterone system 
 RAAS is a hormone system responsible for long term control and regulation of 
both blood volume and BP (Garcia et al., 2003; Ganten et al., 2005). In response to 
decreased blood volume, BP, Na+ and Cl- delivery, the kidney releases a hormone called 
renin into the circulation (Garcia et al., 2003). Circulatory angiotensinogen released from 
liver is an alpha 2 globulin and acts as a substrate for renin. Angiotensin-I (Ang-I) is an 
inactive peptide primarily formed by the action of renin on angiotensinogen (Jackson et 
al., 1986; Jan-Danser, 1996). Ang I converting enzyme (ACE), a kinase, found 
predominantly in lung capillaries converts biologically inactive peptide Ang I to Ang II 
which is biologically active and a potent vasoconstrictor (Brosnihan, 2005). Ang-II 
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increases BP by activating AT1 receptor present in the vasculature and is also responsible 
for the secretion of aldosterone from the medullary cortex (Williams, 1972; Brothers et 
al., 2006). Aldosterone is a Na+ retaining hormone (Williams, 1972). Kidney tubules 
retain Na+ and takes water with it which in turn increases reabsorption of Na+ and water 
into the blood (Pratt, 1982). This process increases blood volume which increases BP due 
to excess Na+ and plasma water retention (Sherwood, 2001). 
 
Besides its role in longterm BP control through blood volume adjustment, RASS also 
intervenes with other regulatory systems. It plays an indirect role in baroreceptor reflex 
action and sympathetic nervous system function (Reid, 1992).  Several reports suggest 
that Ang-II also acts centrally and interferes with the baroreflex control system. 
Normally, in response to high BP, baroreceptors activate and bring down the BP to the 
minimum firing threshold level but RAAS overrides this activity and compromises the 
baroreceptor mediated BP lowering effect (Reid., 1992; Max et al., 2002). During SNS 
activation, endogenous Ang-II plays an important role which increases the sympathetic 
out flow. Increased sympathetic out flow increases HR and BP (Rabbittes et al., 2009). 
RAAS has long been an important therapeutic target for lowering BP compared to other 
pathways. Currently, blockade of this pathway stands alone as a gold standard for 
reduction in preload and afterload which decreases BP, mediates substantial improvement 
in renal impairment, restores endothelial function and improves cardiovascular health 
(Yokokawa et al., 2008; Sever et al., 2009). 
 
1.2.1.2.2.2. Kallikrein kinin system 
 The kallikrein kinin system is an important mediator of kinins that includes 
bradykinin and kallidin (Dendorfer et al., 1994). Both bradykinin and kallidin are 
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vasodilators (Santiago et al., 1995; Marshman et al., 1996). ACE inhibition is the front 
line approach to treat high BP. ACE inhibitors not only reduce Ang-II and subsequent 
aldosterone formation, but also increase the formation of bradykinin. Bradykinin is a 
vasodilator and plays a role in overcoming endothelial dysfunction by augmenting NO 
and prostacyclin (PGI2) generation (Stanisavljevic et al., 2006). Kallidin or Lys-
bradykinin is a decapeptide released from low molecular weight kininogen from the 
tissue kallikrein (Chagas et al., 1992). Both the kinins activate phospolipase A2 (PLA2) 
and facilitate the formation of prostaglandins (PGs) through arachidonic acid cascade 
(Warhurst et al., 1987). Most PGs are beneficial and modulate endothelial dysfunction, 
hence play a protective role against development of hypertension (Granger, 2009). 
 
1.2.2. Local control system  
Local control system regulates blood flow in the tissue or within the regional 
vascular beds (Shepherd et al., 1979; Lautt, 1981 and 1985; Monos et al., 1995). Local 
autoregulation of blood flow is crucial in order to maintain the vascular perfusion 
pressure (Lautt, 1981 and 1985). This system can be classified further into two 
subclasses, myogenic and the metabolic control. 
 
1.2.2.1. Myogenic control 
VSMC of arteries and arterioles respond to the local mediators to optimize 
perfusion which in turn contribute towards the systemic BP. Briefly, VSMC in blood 
vessels are directly affected by changes in BP. Blood flow to a vascular bed depends on 
pressure and resistance (Voelkel et al., 2000). If blood flow is low to a particular organ, 
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due to high resistance then adjacent arterioles normally relax to accommodate the flow. 
Conversely, if blood flow to an organ is very high, adjacent arterioles again contract, thus 
accommodating blood flow to appropriate level (Lautt, 1985). Most importantly, through 
myogenic control, tissues are somewhat self regulating and accommodating to changes in 
pressure, resistance and flow which is very important in terms of tissue perfusion and 
maintenance of systemic BP.  
 
1.2.2.1.1. Endothelium derived vasodilators  
 Endothelium is the monolayer of cells that line the innermost layer of the blood 
vessels which releases several contractile and dilatory mediators.  Vasodilatory factor and 
mediators released from the endothelium are NO, PGI2, endothelium derived 
hyperpolarizing factors (EDHF) and carbon monoxide (Moncada et al., 1979; Furchgott 
et al., 1980; Maines et al., 1997; Christian et al., 1999; Brandes et al., 2000; Naik et al., 
2002). Recently a report suggested that hydrogen sulfide (H2S) has potential to 
hyperpolarize VSMC, thus H2S can also be termed as an EDHF (Yang et al., 2009). 
 
1.2.2.1.1.1. Nitric oxide 
NO is the most important endothelium derived vasodilator and one of the most 
important signaling molecules which contribute to vascular homeostais by inhibiting 
platelet aggregation, vasoconstriction and leukocyte adhesion (Palmer et al., 1987). NO 
keeps endothelium nonthrombotic (Palmer et al., 1987). Many studies have shown that 
NO bioavailability is directly related to endothelial function (Sibal et al., 2009). 
Endothelial dysfunction associated with hypertension, diabetes and all forms of CVD 
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involves, a compromised or reduced state of NO bioavailability (Sibal et al., 2009; 
Kearney et al., 2008). NO is synthesized along with L-citruline from L-arginine by the 
action of nitric oxide synthase (NOS) in the presence of nicotinamide adenine 
dinucleotide phosphate (NADPH), tetrahydrobioptin (BH4) and reduced molecular 
oxygen (Hibbs et al., 1987; Ignarro et al., 1989; Stanger et al., 1994). NO is responsible 
for the maintenance of vascular tone under normal physiological conditions (Palmer et 
al., 1987; Ignaro et al., 1989). Three different types of NOS have been identified. They 
are neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS). Both 
eNOS and nNOS are constitutively present in vascular endothelium and are Ca2+ 
dependent for their activity where as iNOS is expressed in response to inflammatory 
stimuli and does not require Ca2+ for its activation (Paulus et al., 1995). It has been 
reported that although eNOS is constitutively expressed, its expression can be altered or 
augmented by sheer stress, sex hormone, and exercise (Bayraktutan et al., 1998). In these 
conditions, eNOS gene expression increases several fold (Forstermann et al., 1998). On 
the otherhand hypoxia and increased generation of tumor necrosis factor α (TNF α) could 
down regulate mRNA and protein expression level for eNOS (Bayraktutan et al., 1998; 
Forstermann et al., 1998; Li et al., 2002; Anderson et al., 2004). eNOS is predominantly 
present in vascular endothelial cells (EC) and facilitates NO synthesis in the vascular 
endothelium (Paulus et al., 1995; Kobayashi et al., 2001; Li et al., 2006). Endothelium 
derived NO released into the vascular lumen diffuses to adjacent VSMC where it binds to 
the heme moiety of soluble guanylate cyclase (sGC) and increases the formation of cyclic 
guanosine monophosphate (cGMP). cGMP is responsible for phosphorylation of several 
cellular proteins resulting in VSMC relaxation and vasodilatation (Hardman et al., 1969; 
 23 
Katsuki et al., 1997; Rapoport et al., 1983; Ignarro et al., 1989). NO counter balances the 
vasoconstrictor effect exerted by noradrenaline, serotonin, endothelin and Ang-II 
(Rubanyi et al., 1993). Hormones in pathological conditions, increase NO generation, 
contribute to enhanced oxidative stress and pathogenesis of atherosclerosis (Garg et al., 
1989; Karya Y et al., 1989, Ross., 1993). Under physiological settings, NO plays a 
pivotal role in the regulation of BP by relaxing VSMC (Shesely et al., 1996). Several 
reports have demonstrated that eNOS gene knockout mice develop severe hypertension 
(Shesely et al., 1996; Mashimo et al., 1999; D'Souza et al., 2003). Small arterioles 
isolated from eNOS gene knockout mice are resistant to ACh mediated relaxation (Huang 
et al., 1995; Chan et al., 2003). It has already been established that patients with essential 
hypertension have reduced levels of NO due to progressive endothelial dysfunction 
compared to normal individuals (Forte et al., 1997; Forte et al., 2000). Supplementation 
of exogenous NO, administration of NO donors or NO releasing compounds provide 
enormous beneficial effect by improving endothelial function in disease states such as 
hypertension and diabetes (Pearce et al., 2008; Carreiro et al., 2009). Chronic inhibition 
of NOS reduces NO bioavailability and increases peripheral vascular resistance which 
causes BP to increase (Stamler et al., 1994; Mikhail et al., 1997; Rees et al., 1990; Li et 
al., 2000). 
 
1.2.2.1.1.2. Prostacyclin 
PGI2 is a member of the family eicosanoids. Prostacyclin is synthesized in 
endothelial cells from prostaglandin H2 (PGH2) by the action of enzyme prostacyclin 
synthase and exerts its action in a paracrine fashion (Tohgi et al., 1992). PGI2 inhibits 
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platelet aggregation by inhibiting platelet activation and is a potent vasodilator. It binds to 
the platelet G-protein coupled receptor, activates adenylate cyclase and increases the 
level of cyclic adenosine monophosphate (cAMP). It binds to its receptors in the 
endothelium and increases cAMP by activating adenylate cyclase (AC). cAMP activates 
protein kinase A and phosphorylates several proteins which inhibits myosin light chain 
kinase and results in VSMC relaxation. An increased level of cAMP also inhibits platelet 
activation and inhibits intracellular Ca2+ level in VSMC (Moncada et al., 1979). PGI2 is 
reported to be beneficial in the treatment of pulmonary hypertension (Murthy et al., 
2010). In a normal physiological state, there is a dynamic balance maintained between 
endothelial derived contactile and dilatory factors. But, in cardiovascular disease state, it 
has been reported that bioavailabilty of NO and PGI2 decreases substantially due to 
endothelial dysfunction which then contributes to the increased activity of contractile 
factors such as endothelin-1 (ET-1), thromoboxane A2 (TXA2) and Ang II (Endemann et 
al., 2004).  
 
1.2.2.1.1.3. Endothelium derived hyperpolarizing factor 
 It has been proposed that EDHF is a vasodilatory mediator released by endothelial 
cells which leads to NO/PGI2 independent vasodilatation, by hyperpolarizing adjacent 
VSMC (Garland et al., 1996). The mechanism of action and the nature of EDHF are 
controversial, since its effect is heterogenous and varies between species, strain and 
vascular beds (McGuire et al., 2001).  Several endogenous agents are currently 
considered to serve as candidate molecule serving the EDHF function. They are:  K+, 
cytochrome P450 (CYP)-derived metabolite of arachidonic acid called 
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epoxyeicosatrienoic acid (EET), hydrogen peroxide (H2O2), and C-natriuretic peptide 
(CNP) (Dong et al., 1997; Edwards et al., 1998; Fleming et al., 2000; Matoba et al., 2003; 
Chauhan et al., 2003). Finally myoendothelial gap junction (MEGJ) has also been 
proposed to produce an EDHF like effect in many arteries (Griffith, 2004). All EDHF 
mediated responses are abolished in the combined presence of apamin (SKCa channel 
inhibitor), TRAM-34 (IKCa channel inhibitor), and charybdotoxin (IKCa and BKCa channel 
inhibitor) or ouabain (Na+ pump inhibitor), Ba2+ (Kir channel inhibitor) and depolarizing 
potassium (Quilley et al., 1997; Edwards et al., 1998).  
 
1.2.2.1.2. Endothelium derived vasoconstrictor factors 
Under normal physiological conditions, endothium derived vasodilatory and 
contractile mediators are in dynamic balance (Vanhoutte et al., 1986). In disease states 
such as diabetes, hypertension, and atherosclerosis, this balance is no longer maintained 
due to reduced bioavalability of NO (Griffith el al., 1988). Reduced NO production due 
to endothelial dysfunction augments enhanced vasoconstrictor activity by contractile 
mediators. This augmented activity of contractile mediators contributes exponentially to 
VSMC contraction which leads to high BP (Poulis et al., 2008). 
 
1.2.2.1.2.1. Endothelin 
ET was identified in 1988 and is abundant in most vascular tissues (Yanagisawa 
et al., 1988; Rubani et al., 1994; Schiffrin, 1999). It is released from endothelium, and a 
potent vasoconstrictor (Karwatowska et al., 1989; Schinelli et al., 2006). ET exerts its 
effect by acting on ETA and ETB receptors. ET exists in three different isoforms ET-1, 
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ET-2 and ET-3 (Arai et al., 1990; Sakurai et al., 1992; Hynynen et al., 2006). ETA 
receptors are predominantly found in VSMC whereas ETB receptors are predominant in 
endothelial cells (Batra et al., 1993; Hopfner et al., 1999). ETA receptor has 100 fold 
more affinity for ET-1 compared to ET-3. ETB receptor has equal affinity for all the three 
isoforms. ETA receptor activation promotes vasoconstriction and contributes to high BP. 
ETB receptor activation releases NO and decreases BP by relaxing VSMC. ETB receptor 
has subtypes called ETB1 and ETB2. ETB1 on the endothelial cells mediates vasodilatation 
and ETB2 receptors on the VSMC mediate vasoconstriction (Devenport et al., 1994). The 
ETB receptor also serves as a “clearance receptor” for ET (Muramatsu et al., 1997; 
Kedzierski et al., 2001). Physiologically ET plays an important role in BP regulation, but 
in pathological conditions ET predominantly constricts blood vessels and contributes to 
vascular diseases (Noll et al., 1996; Benigni., 2000; Kedzierski et al., 2001). The ET 
antagonist bosentan is approved for treatment of pulmonary arterial hypertension (PAH). 
Sitaxentan sodium is currently under Food and Drug Administrations (FDA) review for 
the treatment of PAH (Dupuis et al., 2008; Abman, 2009). Bosentan was approved in 
Europe and submitted for, approval by FDA for the treatment of scleroderma such as 
ulcers in the fingers and toes (American Physiological Society, 2009). 
 
 
1.2.2.1.2.2. Thromboxane A2 
Membrane phospholipids liberate arachidonic acid in response to physiological as 
well as pathological stimuli. Arachidonic acid down the road is converted to prostanoids 
by cyclooxygenase (COX) enzyme (Tohgi et al., 1992). Prostanoids are local in their 
action (Smith W L., 1992). Thromboxane A synthase is the enzyme that regulates the 
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synthesis of TXA2 (Tohgi et al., 1992). Both TXA2 and PGI2 are degraded spontaneously 
under physiological conditions, whereas other PGs are enzymatically inactivated 
(Narumya et al., 2001). Although both PGI2 and TXA2 have opposite actions, they play 
an important role in the maintenance of vascular homeostasis. PGI2 is produced by ECs, 
is a potent vasodilator and inhibits VSMC proliferation and platelet aggregation. 
Conversely, TXA2 synthesis that occurs predominantly in VSMC binds to its 
thromboxane receptor and promotes platelet aggregation, vasoconstriction and VSMC 
proliferation. In conditions like hypertension, diabetes, atherosclerosis and vascular 
disease, the balance between PGI2 and TXA2 is altered due to progressive endothelial 
dysfunction. Less availability of PGI2 and NO due to endothelial dysfunction exaggerates 
TXA2 mediated vasocontractile effect, contributing to CVD (Abe et al., 1995; Ruschitzka 
et al., 1998). 
 
1.2.2.1.2.3. Free radicals 
Oxidative stress is one of the factors which contribute to vascular disease by 
generating free radicals. Increased level of free radical decreases superoxide dismutase 
(SOD), vitamin E and NO production by inhibiting NOS and PGI2 synthase (Vijay et al., 
1993; Vidal et al., 1998; Davidge et al., 2001). Free radical generation in turn is 
responsible for the production of superoxide anion and TXA2 generation (de Artinano et 
al., 1999; Nakazono et al., 1999). Excess production of free radicals has been shown to 
increase vasoconstriction and VSMC proliferation, thereby contributing to 
pathophysiology of many diseases that include CVD, diabetes, artherosclorosis, and 
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rheumatoid arthritis (Giugliano et al., 1996; Aviram, 2000; Davi et el., 2005; Van et al., 
2006).  
 
1.2.2.2. Metabolic control 
During metabolic activities, the vasculature produces different metabolites, such 
as carbon dioxide (CO2), adenosine diphosphate (ADP), organic acids, K+ and H+ 
(Murrent et al., 2000). Increased metabolic activity increases the amount of metabolites 
that accumulate in the cells. They can exert a vasodilatory response by directly 
stimulating the arterioles to increase blood flow. This increase in blood flow decreases 
the accumulation of these metabolites. Subsequently cells try to contract and come back 
to its preactivation level (Murrent et al., 2000). Although VSMC contraction and 
relaxation depends on various dilatory and contractile mediators released from 
endothelial cells, increases in metabolic activity is one of the factors that also contribute 
to vasodilatation (Rong., 1998; Akata., 2007; Wong et al., 2009). 
 
1.3. Management of hypertension 
Our knowledge regarding the underlying mechanisms related to the 
pathphysiology of hypertension is limited. Currently, the overall approach to prevention, 
management by treatment with antihypertensive medications and appropriate patient care 
have been changed and improved. Over the years, new classes of pharmacological agents 
have also been introduced for the management of hypertension. Several new guidelines 
are proposed in the joint coordinating committee (JCC-7). JCC-7 and Canadian 
Hypertension Education Program (CHEP) guidelines provide current updates on 
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detection, evaluation, treatment and prevention of hypertension. In the management of 
hypertension, the following antihypertensives are in use; diuretics, β-blockers, α1 
blockers, ACE inhibitors, angiotensin receptor blockers (ARBs) and calcium channel 
blockers. The renin inhibitor, aliskiren, is approved for the treatment of primary 
hypertension and has already shown promising results in clinical trials over other existing 
antihypertensives (Schmieder et al, 2009).  
1.4. Vascular action of peptides 
Many physiologically active peptides with effective antihypertensive properties 
have been discovered from different food proteins (Karaki et al., 1990; Yoshikawa et al., 
2000). Some of them are suggested to have an ACE inhibition like property and are 
claimed to have potential in the treatment of hypertension (Fujita et al., 2000, Arai et al., 
2001, Sun et al., 2009). Recently a peptide with amino acid sequence, Lys-val-Leu-Pro-
val-Pro has been shown to decrease BP in hypertensive rats but the pharmacokinetic 
profile and mechanism of action is not that clear (Liu et al., 2007). There are some 
peptides derived from milk fermented by E. faecalis a bacterium with amino acid 
sequence LHLPLP, LHLPLPL, LVYPFPGPIPNSLPQNIPP, VLGPVRGPFP, and 
VRGPFPIIV have been shown to inhibit ACE and reduces BP in hypertensive rats 
(Miguel et al., 2006). 
 
1.5. Vascular action of amino acids 
Amino acids are building blocks of proteins and participate in metabolism. Amino 
acids are critical for the formation of coenzymes and serve as precursor for the synthesis 
of heme (Cox et al., 2005).  They play an important role in nutrition (Young, 1994). 
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Several amino acids serve as excitatory as well as inhibitory neurotransmitters in the 
brain (Munro et al., 1986). Many reports have demonstrated that amino acids exert 
distinct vascular effect by modulating or activating membrane ion channels, receptors and 
transporters (Sgaragli et al., 1972). A role of amino acids in enhancing cardiovascular 
health has been demonstrated (Barinaga, 1990). Over a period of time several amino 
acids are suggested to play a cardiovascular protective role and lower BP.  Briefly they 
are discussed below.  
 
Taurine: Taurine is a naturally occurring organic acid. It is a major constituent of bile 
and is found in small intestine, in many mammalian tissues including human beings 
(Bouckenooghe et al., 2006; Brosnan et al., 2006). Taurine biosynthesis takes place in the 
pancreas via the cysteine sulphonic acid pathway.  Taurine has beneficial effects in the 
proper maintenance of the skeletal system (Warskulat et al., 2004). It reduces fatty liver 
deposits and decreases liver cirrhosis in rats (Kerai et al., 1998). Oral supplementation of 
taurine in drinking water decreases BP in both spontaneously hypertensive rats (SHR) 
and in stroke prone SHR strains (Nara et al., 1978). Central administration of taurine (100 
- 400 μg/kg) evokes a dose dependent fall in mean arterial pressure (MAP) in both 
anesthetized as well as conscious rats (Petty et al., 2002). Taurine and its potential 
cardiovascular health benefits have been demonstrated recently (Xu et al., 2008). Taurine 
is known to reduce ischemic disease and stroke (Yamori et al., 2009). Oral administration 
of taurine 6 g/day for a period of 7 days led to significant reduction in systemic BP in 
patients with essential hypertension (Militante et al., 2002). In rat and human studies, 
taurine mediated fall in MAP appears to be associated with reduction in overactive 
sympathetic nervous system (SNS) activity (Millitante et al., 2002; Hano et al., 2009). 
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The cardio protective effect of taurine is considered to act through multiple mechanisms 
(Millitante et al., 2002). 
 
L-alanine: L-alanine, a non-essential amino acid, is found mostly in meat, egg, milk, 
beans, nuts and vegetables. It is a proteinogenic amino acid and nonpolar by nature. L-
alanine administration decreases MAP in rodents (Garagli et al., 2002). L-alanine is 
reported to inhibit exploratory behaviour in SHR strain (Liljequist et al., 1982). 
 
Tyrosine: Tyrosine is found in milk, meat, egg, banana and almonds. Dietary 
supplementation of tyrosine is reported to have the potential to decrease BP in 
hypertensive animals (Sveda et al., 1979). 
 
Tryptophan: Tryptophan is an essential amino acid and is synthesized by plants and 
micro organisms from shikimic acid and anthranilate (Radwanski et al., 1995).  It is a 
precursor for central neurotransmitter, 5-hydroxytryptamine/serotonin (Wolf et al., 1984). 
Some studies suggest that tryptophan and its analogs could decrease BP in normotensive 
and hypertensive rat models (Wolf et al., 1984). 
 
L-arginine: Studies have shown that oral supplementation of L-arginine is highly 
effective in reversing endothelial dysfunction in several disease states (Rossitch et al., 
1991). Oral or intravenous administration of L-arginine has been shown to be beneficial 
in preventing atherosclerosis, increases coronary blood flow in patients with heart disease 
and in alleviating intermittent claudication. L-arginine infusion lowers BP and prevents 
reclosing of arteries after balloon angioplasty (Maxwell et al., 1998). However, Schulman 
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et al have reported that, the addition of L-arginine to post infarction therapy did not show 
any improvement in vascular stiffness (Schulman et al., 2006). Instead, it may be 
associated with increased post infarction mortality. Thus, it shuld not be recommended to 
patients who have suffered acute myocardial infarction. 
 
γ-amino butyric acid: γ-amino butyric acid (GABA) is an inhibitory neurotransmiter.  
Intra-cisternal infusion of GABA produces hypotensive effect in rodents (Brown et al., 
1978).  
 
Glutamic acid: Recently, a clinical trial has demonstrated that dietary supplementation 
with glutamic acid is associated with a significant BP lowering effect in hypertensive 
patients (Stamler et al., 2009).  
 
L-serine: L-serine is a non-essential amino acid synthesized in the body from other 
metabolites. It is polar in nature and plays an important role in purine and pyrimidine 
synthesis, responsible for cell growth and survival. L-serine is conditionally essential in 
cell culture (McCoy et al., 1956). Oral supplementation with L-serine reduces methionine 
induced homocysteine formation along with a reduction in γ-glutamyl transpeptidase 
activity in humans (Verhoef et al., 2004). Close association of increased levels of plasma 
homocysteine and γ-glutamyl transpeptidase activity in metabolic syndrome and CVD 
has been demonstrated (Lee et al., 2007). In humans, oral supplementation of L-serine 
(>1.5 g/day) is found to be effective in the treatment of depression, schizophrenia, 
chronic fatigue syndrome and rare inborn errors of metabolism which are likely to be 
associated with L-serine deficiency. (Addington.et al., 1999; de Koning et al., 2003 and 
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2006). Our laboratory has shown that acute intravenous administration of L-serine evokes 
a dose dependent fall in MAP and it was more profound in two well established rat 
models of hypertension (Mishra et al., 2008a; Mishra et al., 2008b; Mishra et al., 2010). 
L-serine evoked vasodilatation is endothelium dependent but is not mediated through NO 
or PGI2 (Mishra et al., 2007).  Moreover, both the vasodilator and antihypertensive effect 
of L-serine is more profound in L-NAME treated rats. This vasodilator and 
antihypertensive effects of L-serine are blocked in the presence of SKCa and IKCa 
blockers, such as, apamin and charybdotoxin respectively. The decrease in MAP evoked 
by D-serine which is a metabolite of L-serine is much less in comparison to L-serine. In 
contrast, glycine which serves both as a precursor/metabolite to L-serine, evoked a 
decrease in the MAP in normotensive rats and an increase in the MAP in hypertensive 
rats in a dose dependent manner (Mishra et al., 2009). L-serine can be derived from or 
give rise to glycine. Although both L-serine and glycine decrease MAP in normotensive 
animals their magnitude of relaxation and sensitivity are different. Unlike L-serine, 
glycine mediated responses are sensitive to NMDA antagonists, such as, MK-801 and 
memantine.  Interestingly, L-serine evokes a profound fall in MAP where as glycine 
evokes an elevation in MAP in hypertensive rat models (Mishra et al., 2008b). 
 
These studies provide the rationale for establishing in vitro and in vivo studies for the 
direct vascular effects of glycine which is different from L-serine in hypertensive rats. 
 
1.6. Glycine 
 Glycine one of the 20 naturally occurring amino acids that was discovered by the 
French Pharmacist, Henery Bracconut in 1820. The name glycine came from a Greek 
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word that translates as“for sugar”.  Glycine is a sweet tasting, non essential amino acid, 
derived from other amino acids in the body such as L-serine and threonine. It is lipophilic 
in nature with a molecular weight 75.07 dalton and molecular formula C2H5NO2. It is 
required for the systhesis of deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), 
participates in the synthesis of bile acids, adenosine triphosphate (ATP), porphyrins, 
hemoglobin, peptides, proteins, creatine, glycogen, glutathione and L-serine in the body. 
It is conditionally essential in the systhesis of purines, heme and glutathione (Cox et al., 
2005). The plasma concentration of glycine is 227.5 µmol/L in human and in rat the 
plasma concentration of glycine is 272 ± 25 (Polge et al., 1997; Palou et al., 1977; 
Christensen et al., 1946; Bonnet et al., 2007).  Glycine serves as an inhibitory 
neurotransmitter in the CNS and acts as a co-agonist at N-methyl D-aspartate (NMDA) 
glutaminergic receptor. Glycine has the potential to increase growth hormone and is 
involved in the proper functioning of immune system (Kasai et al., 1978 and 1980). It 
plays an important role in the repair of damaged tissue and promotes tissue healing 
(Harvey et al., 1985). Glycine in combination with alanine and glutamic acid has been 
shown to have beneficial effect in reducing the prostate size (Feinblatt et al., 1958; 
Dumrau et al., 1962; Osiecki et al., 2004). Although glycine is not essential in the diet, it 
serves as an important micronutrient for the proper functioning of the body (Osiecki et 
al., 2004).  
 
1.6.1. Sources of glycine 
Glycine is the most abundant amino acid found in the body. It is present in all 
cells of the body. A large amount of glycine is found in the skin, connective tissue and in 
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the prostate cells (Osiecki et al., 2004). Glycine is plentily available in protein rich foods 
such as meat, fish and milk products (Osiecki et al., 2004). Glycine serves as a precursor 
to L-serine and under certain conditions; L-serine is also metabolized to glycine in the 
presence of serine hydroxyl methyltransferase (SHMT) and tetrahydrofolate (THF). Thus, 
L-serine and glycine are interconvertible depending on tissue availability of SHMT and 
THF. Table 2 lists the amount of glycine in milligram present in some of the dietary 
protein products. 
 
4644100 gmMozzarella, part skim 
1922½ fillet (154 gm)King mackerel, cooked
1886100 gmLean veal leg, cooked
19731 fillet (184 gm)Atlantic cod, cooked
2133140 gmChicken breast, no skin, 
roasted
2199100 gmLean round beef, 0% fat
23911 can (171 gm)Tuna, canned in oil
3458329 gm1/2 Chicken - no skin 
4562306 gm1/2 Turkey breast - no 
skin
Glycine (mg)AmountFood
 
Table 2. Amount of glycine (mg) in dietary protein products. 
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1.6.2. Biosynthesis of Glycine 
Glycine is a non essential amino acid that is derived from other amino acids such 
as L-alanine, L-serine and L-threonine in the body (Figure 1). In most living organisms 
SHMT catalyses this conversion in presence of a cofactor called pyridoxal phosphate 
(Nelson et al., 2005). Glycine also can be biosynthesized from isolated chloroplasts (Shah 
et al., 2001). Vertebrate liver produces an enzyme called glycine synthase participates in 
the glycine cleavage system (GCS) which catalyzes this synthesis but this process is 
reversible (Cox et al., 2005).  
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L-alanine L-glycine
L-glycineL-serine
L-glycine
Glyoxylate Pyruvate
AGX I
SHMT 2
SHMT 1
THF 5, 10-methylene THF
H2O
L-threonine
GLY I
Acetaldehyde
Glycine biosynthesis
 
 
Figure 1. Schematic representation of glycine biosynthesis from L-alanine, L-serine and 
L-threonine.  
 
AGX1, Alanine glyoxylate aminotransferase 1; GLY, Glycine; SHMT, serine hydroxyl 
methyltransferase; H2O, water; THF, tetrahydrofolate;  
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1.6.3. Glycine and its metabolism  
 Glycine metabolism occurs through three different pathways (Cox et al., 2005). 
The most important pathway is catalysis of glycine by glycine synthase or glycine 
cleavage enzyme. The second pathway involves an enzyme called serine 
hydroxymethyltransferase (SHMT) that converts glycine to L-serine and subsequently L-
serine is converted to pyruvate in the presense of another enzyme called serine dehydrase. 
The third pathway involves the conversion of glycine to glyoxylate by D-amino acid 
oxidase. Glyoxylate is then oxidised to oxalate in the presence of an enzyme called 
hepatic lactate dehydrogenase. This reaction requires nicotinamide adenine dinucleotide 
(NAD+)  to produce oxalate (Cox et al., 2005). Thus, glycine and L-serine metabolism are 
linked to glycolytic pathway of glucose metabolism. 
 
1.6.4. Glycine and its receptor 
 Glycine is lipophilic in nature and can not be ionized since it does not exhibit 
chirality; moreover its R-group is a single hydrogen atom (Kleuss et al., 2003; 
Biochemistry of Amino Acids, 2009). Gylcine can easily cross the blood brain barrier 
(BBB) and exerts its central effect (Danysz et al., 1998). Primarily, glycine acts on its 
receptors that includes both the receptor subtypes and mediate its response (Biochemistry 
of Amino Acids, 2009). The first glycine receptor identified was a strychnine-sensitive 
one, found mainly in the spinal cord and lower brain stem (Cimino et al., 1996; Danysz et 
al., 1998; Jiang et al., 2004; Lynch, 2004). The other one is strychnine-insensitive and 
found in different areas of brain in the following order, hippocampus > cerebral cortex > 
caudate putamen > thalamus > cerebellum (Malosia et al., 1991).  Glycine is considered 
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to be an inhibitory neurotransmitter in the brain and spinal cord (Lynch, 2004; Schmidt et 
al., 2006). Glycine receptors are coupled with inhibitory neurotransmitter gated Cl- 
channels localized in the presynaptic membranes (Ehrlich et al., 1999; Turecek et al., 
2001; Lynch, 2004). Glycine receptor has two subtypes, glycine-A and glycine-B 
(Danysz et al., 1998). Glycine-A subtype consists of α and β subunits. The α subunit is 
again subdivided into α1, α2, α3  and α4  isoforms (Malosia et al., 1991; Lynch, 2004). The 
function of the single β subunit is to anchor glycine receptors to the subsynaptic 
cytoskeleton with the help of cytoplasmic protein known as gephyrin (Lynch, 2004). 
Glycine-B subtype on the other hand is a strychnine insensitive receptor, known to serve 
as coagonist at glycine binding site of NMDA glutaminergic receptor (Danysz et al., 
1998). The classical action of glycine by acting on its presynaptic glycine-A receptors 
that includes all isoforms (α1-4) triggers normally a very weak depolarizing Ca2+ current 
due to Cl- influx. This weak Ca2+ current not only helps in releasing the neurotramsmitter 
but also elicits an inhibitory post synaptic action potential (Turecek et al., 2001). Unlike 
the classical inhibitory action mediated by glycine by acting on its subtype glycine-A 
receptor, glycine is also required for activation of the NMDA receptor along with 
glutamic acid to cause influx Ca2+ (Danysz et al., 1998; de Koning et al., 2003).  
 
1.6.5. Vascular action of glycine 
Glycine is known to serve as an inhibitory neurotransmitter in brain and spinal 
cord. Glycine primarily opens chloride ion channels by activating its receptor. Chloride 
makes neuronal cell membranes more negative, and hyperpolarizes the neuron. This 
hyperpolarization exerts an inhibitory potential (Lynch, 2004). Glycine is a coagonist at 
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NMDA glutaminergic receptor along with NMDA and D-serine. Glycine prevents 
apoptosis in endothelial cells (Zhang et al., 2000).  Glycine intake has been shown to 
decrease adipose cell size, plasma free fatty acid and BP in sucrose-fed rats (Hafidi et al., 
2004). This BP lowering effect of glycine is suggested to be associated with a reduction 
in oxidative stress (Hafidi et al., 2006). Dietary supplementation with glycine has the 
potential to reverse the elevated systolic BP encountered in pregnant rats on a low protein 
diet (Jackson et al., 2002). Glycine regulates the production of pro-inflammatory 
cytokines in lean and mono sodium glutamate-treated obese mice (Aguilar et al., 2008). 
Glycine is reported to improve microcirculation and minimize reperfusion injury in rat 
liver (Zhong et al., 1996). Recently a report suggested that glycine protects human 
intestinal epithelial cells from oxidative damage (Howard et al., 2009). Glycine 
participates in synthesis of glutathione and this protective effect of glycine is probably 
due to restoration of glutathione. Another study suggested that glycine mediated 
cytoprotection in kidney and liver is independent of glutathione (Weinberg et al., 1992; 
Dickson et al., 1992). Another report suggests that glycine decreases oxidative stress 
induced by activation of inflammatory mediator, interleukin-2 (IL-2) (Katayama et al., 
2007).  Dietary glycine protects against colitis induced intestinal injury in rat models 
(Tsune et al., 2003). It has been shown that glycine transporter 1 (GLYT1) in gut 
epithelial cells protect the gut from inflammation (Mc Cole., 2010). Glycine intake may 
be beneficial in the treatment of inflammatory bowel syndrome. Glycine and its 
protective effect are extensively reported in the literature, but the effect of glycine 
administration in the management of CVD has not been addressed so far. Recently, we 
reported for the first time that L-serine decreases MAP in normotensive rats and this 
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effect is more pronounced in hypertensive rat models. In contrast administration of 
glycine, a precursor/metabolite of L-serine, decreased MAP in normotensive rats, but 
increased MAP in hypertensive rat models (Mishra et al., 2008a; Mishra et al., 2008b). 
The L-serine mediated depressor response is associated with a decrease in splanchnic 
vascular resistance in hypertensive rat models (Mishra et al., 2010). These studies provide 
impetus to look at the specific regional vascular beds, which may be contributing to this 
pressor response evoked by glycine in hypertensive rat models. 
 
1.6.6. Glycine and its possible therapeutic uses   
Glycine (2g/day) has been used along with other neuroleptics as add on therapy in 
the treatment of schizophrenia (Buchanan et al., 2007). Trimethyl glycine has been 
reported to have potential in the treatment of steatohepatitis (Miglio et al., 2000; Angulo 
et al., 2001; Abdelmalek et al., 2009). Long term glycine intake protects against oxidative 
stress. This suggests that its administration may be considered in the treatment of 
hypertension (Hafidi et al., 2006). A double blind study suggested glycine intake is useful 
in blood glucose regulation (Martinez-Abundis et al., 2003). Anhydrous trimethyl glycine 
is approved by FDA in the treatment of homocystinuria (Holm et al., 2005). Glycine 
being an inhibitory neurotrasmitter has potential in the management of neurologic 
disorders, hyperactivity, seizure, depression and bipolar disorders (manic phase) (Danysz 
et al., 1998; Hashimoto et al., 2006; Buchanan et al., 2007).  
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CHAPTER 2. HYPOTHESIS AND RATIONALE 
 
2.1. Background and rationale for the present study 
Our laboratory has primarily engaged in establishing the cardiovascular effect of 
novel peptides like ghrelin and segetalins. Ghrelin is a peptide hormone consisting of 
single chain of 28 amino acids and was discovered in 1999 (Kojima et al., 1999). It is 
released from the stomach and it is involved in growth hormone secretion by activation of 
ghrelin receptor GHSR1a/ GRLNR, a cell surface G protein coupled receptor that 
enhances phospholipase C (PLC) activation and elevation of cytosolic free calcium 
(Kojima et al., 1999; Wren et al., 2000; Cunha et al., 2002). Several laboratories have 
shown that, besides its classical physiological actions of increasing growth hormone 
release and decreasing food intake, exogenous administration of ghrelin evokes 
vasodilatation and a fall in MAP. It improves NO bioavailability and normalizing the 
imbalance between ET-1/NO within the vasculature of individuals with metabolic 
syndrome (Shinde et al., 2005; Manfredi et al., 2010). Our laboratory has demonstrated 
that the vasodilator responses of ghrelin in the perfused mesenteric vascular bed in rat 
models are not due to activation of ghrelin receptor, GHSR1a. Even des-octanoyl (des-
acyl) ghrelin, which is a precursor and a metabolite of ghrelin, but not a ligand of 
GHSR1a, produced similar type of vasodilator response as ghrelin. These data suggested 
that the vasodilator response evoked by GRLN and des-acyl GRLN is not due to 
activation of GHSR1a (Moazed et al., 2009). Interestingly, several N-terminal peptide 
fragments of des-acyl GRLN also evoked a similar vasodilator response to des-acyl 
GRLN when endothelium was intact (Moazed et al., 2009). Serine residues are abundant 
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in the N-terminal sequence of des-acyl ghrelin (Kojima et al., 2001; Matsumoto et al., 
2001). Also studies from different laboratories demonstrated that N-arachidonyl L-serine 
evoked vasodilatation in rat mesenteric arteries and in abdominal aorta when endothelium 
is intact (Milman et al., 2006). Thus, it is likely that the vasodilatation and fall in MAP 
evoked by ghrelin and its analogs could be due to serine residues present on the N-
terminal sequence of ghrelin. This prompted us to undertake detailed studies to 
investigate the vascular responses to L-serine. In vitro addition of L-serine evoked 
endothelium-dependent but NO or PGI2-independent vasodilatation (Mishra et al., 
2008a). Moreover, both in vitro (vasodilator response) and in vivo (the fall in MAP) 
studies  established that the responses to L-serine were significantly higher in rats with 
elevated BP following NOS inhibition by four days of oral treatment with L-NAME (0.7 
mg/ml in drinking water given ad libitum). L-serine-induced concentration-dependent 
vasodilatation in the third order branches of rat mesenteric arterioles were abolished 
either following endothelial denudation or in the combined presence of SKCa and IKCa 
inhibitors, apamin and charybdotoxin/TRAM-34, respectively. Similarly, the dose-
dependent fall in MAP evoked by L-serine was abolished in rats that were pretreated with 
apamin and charybdotoxin (Mishra et al., 2008a and 2008b). Like L-serine, D-serine also 
evokes a dose dependent fall in MAP. This decrease in MAP is much less in comparison 
to L-serine. In contrast, glycine which serves both as a precursor/metabolite of L-serine 
evokes a decrease in MAP in normotensive rats and an increase in MAP in hypertensive 
rats (Mishra et. al., 2008b). The effects of both L-serine and glycine were clearly dose-
dependent. While a number of studies have suggested that glycine is cardiovascular 
protective, paradoxically, in both SHR and L-NAME treated hypertensive rats we have 
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reported that acute intravenous administration of glycine evokes increases in MAP 
(Mishra et al., 2008b). While apamin+charybdotoxin treatment abolished the fall in MAP 
evoked by L-serine, the responses to glycine (fall in MAP in normotensive rats and 
increase in MAP in hypertensive rat models) remained unaffected in rats that were 
subjected to combined pretreatment with apamin+charybdotoxin. These data confirmed 
that the altered responses to glycine (fall in MAP in normotensive rats vs. elevation in 
MAP in hypertensive rat models) are not mediated by activation of EDHF since 
responses were sensitive to inhibition by apamin+charybdotoxin/TRAM-34 (SKCa and 
IKCa inhibitors).  However, pretreatment with the NMDA antagonist, MK-801, abolished 
glycine mediated responses (Mishra et al., 2008b).  The mechanism associated with the 
opposing effects of glycine in normotensive vs. hypertensive rat models has not been 
fully elucidated and it is the intent of the present work to establish the mechanism. 
Moreover, the regional vascular beds that respond to glycine have not been established.  
A subsequent study from our laboratory has shown that the systemic hemodynamic 
responses of a profound fall in MAP evoked by L-serine in hypertensive rat models is 
mainly due to a decrease in splanchnic vascular resistance in L-NAME treated 
hypertensive and SHR models (Mishra et.al., 2010). It is unclear whether glycine evoked 
changes occur in the same regional vascular beds.   This remains to be tested and it is the 
major focus of the present study. 
 
2.1.1. Rationale for the regional hemodynamic study 
Several studies using dietary glycine in diverse animal models and circumstantial 
evidence from human studies have indicated that glycine has potential to improve 
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endothelial function by reducing oxidative stress which subsequently contributes to the 
antihypertensive effect (Talman et al., 1989; Jackson et al., 2002; Yin et al., 2002; Hafidi 
et al., 2004; Hafidi et al., 2006). In support of these observations, a number of studies 
have also pointed out that glycine induces renal vasodilatation perhaps by activating 
glutamate NMDA receptors (Deng et al., 2002). NMDA receptor activation increases 
Ca2+ influx. If this exists in vascular ECs, glycine would increase generation of 
vasodilator mediators such as NO (following Ca2+ induced activation of NO, PGI2 via 
PLA2 activation and EDHF via activation of SKCa/ IKCa). On the other hand, NMDA 
receptor activation in VSMC could result in vasoconstriction and a concomitant increase 
in systemic vascular resistance. The presence of NMDA receptors has been shown in 
aortic smooth muscle cells (Crespi et al., 2000). Some reports suggested that dietary 
intake of glycine reduces BP (Jackson et al., 2002). On the other hand our work has 
shown that, L-serine mediated vasodilatory and hypotensive effect was not shared by 
glycine since combination of SKCa and IKCa inhibitors abolished L-serine mediated effect 
but not glycine mediated response.  However, a selective NMDA antagonist MK-801 
abolished glycine mediated effect but not L-serine effect. Clearly L-serine and glycine 
evokes their vascular effect in normotensive and hypertensive rat models via different 
mechanisms, although glycine serves as a precursor and metabolite of L-serine (Mishra et 
al., 2008b).  We have already shown in another study that L-serine evoked hypotensive 
effect is due to decrease in splanchnic vascular resistance (Mishra et al., 2010). 
Therefore, it is now important to explore the systemic and peripheral hemodynamic effect 
of glycine in normotensive as well as hypertensive rat models to establish which vascular 
beds are sensitive to glycine.  
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2.1.2. Rationale for the in vivo studies 
In addition to MK-801, another NMDA receptor antagonist memantine (another 
open channel blocker) could be used to confirm glycine induced systemic hemodynamic 
effects are indeed mediated by vascular NMDA receptor activation. The overall effect of 
glycine on rat vascular NMDA receptors are minimal since much of glycine is 
transported by amino acid transporter into the cells and when this transport is blocked by 
employing a glycine transporter inhibitor, N-methyl glycine, sarcosine, as expected 
extracellular glycine levels would increase and this could result in a more profound effect 
of glycine on vascular NMDA receptors to promote Ca2+ influx in both normotensive and 
hypertensive rats.  
 
2.1.3. Rationale for the in vitro studies 
While these studies could provide pharmacological evidence from functional type 
studies for the recruitment of vascular NMDA receptors, these in vivo type experiments 
alone do not provide a mechanistic explanation for the fall in MAP in normotensive vs. 
elevation in MAP in hypertensive rats although both of these effects of glycine could be 
attenuated by more than one NMDA antagonists. To address this issue, in vitro type 
experiments will be performed using isolated ring preparations of rat aorta. The existence 
of NMDA receptors on rat aortic smooth muscle cells/rat aortic tissue has been 
previously demonstrated (Qureshi et al., 2005).  However, the effects of glycine has not 
been investigated using aortic rings from either normotensive or hypertensive rat models. 
The aim of this present study is to provide an explanation for the observed hemodynamic 
effects of glycine by employing this in vitro study. In these experiments, increasing 
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concentrations of glycine (100 µM to 3.0 mM) will be used to investigate whether 
glycine affects basal vascular tone and whether this would be exaggerated in aortic rings 
isolated from age-matched SHR and L-NAME treated WKY rats.  It would be interesting 
to examine whether the changes in basal tone evoked by glycine are attenuated in the 
presence of NMDA antagonist(s). Similarly, phenylephrine (PE) constricted rings 
whether addition of glycine evokes vasodilatation via promoting NO release following 
activation of endothelial NMDA receptors could be assessed. Such a mechanism could be 
more active in normotensive rats thereby contributing to the fall in MAP subsequent to 
glycine administration. In contrast in hypertensive rat models, with the presence of 
endothelial dysfunction and reduced NO bioavailability, there is exaggerated vascular 
tone following glycine administration. To summarize, intracisternal administration of 
glycine promotes a fall in BP that was demonstrated as early as 1972 (Sgaragli et al., 
1972; Pavan et al., 1972).  Glycine serves a role as a central neurotransmitter. While 
dietary glycine or chronic administration of glycine could affect hemodynamic responses 
via alterations in centrally or other peripherally mediated mechanisms, the direct 
peripheral vascular effects of glycine have not been demonstrated. Thus, it is first of all 
important to establish whether acute intravenous administration of glycine evokes 
changes in BP and associated hemodynamic parameters. Based on the above, the 
following working hypothesis has been formulated. 
 
2.2. Working hypothesis  
Acute intravenous administration of glycine evokes depressor response in 
normotensive WKY rats and a pressor response in hypertensive rats (Mishra et al., 
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2008b). This opposing effect of acute glycine induced alteration in MAP is mediated by 
both vascular and endothelial NMDA receptors. In normotensive WKY rats, with intact 
functionally active endothelium, pharmacological doses of acute intravenous glycine 
administration increases NO generation that decreases MAP due to NO-mediated 
vasodilatation occurring in select regional vascular beds that are sensitive to glycine. The 
significant level of vasodilatation in these vascular beds leads to reduction in TPR and a 
concomitant fall in MAP.  In contrast, in hypertensive rat models when NMDA receptor 
mediated endothelial mediators are blunted such as in SHR and L-NAME-induced 
hypertensive WKY rats, glycine administration might promote increased vascular tone 
via activation of finite population of NMDA receptors present in VSMCs. This leads to 
increases in TPR and elevated MAP. Glycine is non polar in nature and might be eliciting 
its effect by actvating peripheral vascular NMDA reptors present on the endothelium (in 
normotensive states) to account for this opposite effects of fall in MAP in normotensive 
and increase in MAP in hypertensive rat models. 
  
2.3. Experimental strategy 
 
Specific experimental objective 1:  Regional hemodynamic study  
 To measure the changes in regional blood flow and regional vascular resistance 
following acute intravenous administration of glycine in age and sex-matched 
normotensive (14 week old male WKY) and hypertensive rat models (14 week old male 
SHR and 14 week old L-NAME-treated WKY) using fluorescent microsphere 
distribution technique. The responses to glycine will be determined in these models either 
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in the presence or absence of NMDA antagonist, MK-801. All rats were allowed to fast 
over night. 
 
Specific experimental objective II: In vivo study 
To measure the changes in systemic hemodynamic parameters such as TPR, 
MAP, HR, and CO following acute intravenous administration of glycine in age and sex-
matched normotensive (14 week old male WKY) and hypertensive rat models (14 week 
old male SHR and 14 week old L-NAME-treated WKY). In addition, administration of 
sarcosine, a glycine transporter inhibitor, should augment the depressor and pressor 
responses to glycine in normotensive and hypertensive rats respectively. Also the changes 
in MAP, during acute glycine administration will be tested in the presence and absence of 
at least two different NMDA antagonists, MK-801 and memantine, in all the three rat 
models will be determined. 
 
Specific experimental objective III:  In vitro study using rat aortic rings  
 To determine the changes in basal tone before and after incubation with 
increasing concentrations of glycine in rat aortic rings isolated from WKY and SHR 
strain.  Also we will examine whether the responses evoked by glycine in vessels of these 
strains are affected by incubation with optimal concentrations of NMDA antagonist (MK-
801). The changes in basal tone induced by glycine will be determined under the above 
incubation conditions in both endothelium intact and endothelium denuded vessels. In 
addition, the effect of increasing concentrations of glycine will be evaluated in PE 
constricted rings. Finally, the goal of this study is to establish whether or not the 
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observations made in the in vitro model correspond/correlate with the changes seen in the 
in vivo model.    
 
2.3.1. Choice of different vascular tissue and different animal models 
 Different animal models of hypertension have been developed. Although the 
existing animal models of hypertension are expected to exhibit similar characteristics 
encountered in human essential hypertension, unfortunately no single hypertensive rat 
model clearly addresses all the issues. There are two classes of animal models of 
hypertension developed; genetic and non-genetic models. Spontaneously hypertensive rat 
(SHR) represents a genetic rat model of hypertension. Non genetic rat models of 
hypertension are developed either by specific surgical methods or by induction/ inhibition 
by chemicals and pharmacological agents. Some of the non genetic rat models of 
hypertension are as follows: Dhal salt sensitive rat strain, deoxycorticosterone (DOCA) 
treated rats, and chronic NOS inhibitor treated rats. The latter model develops 
hypertension more similar to the prototype for the non-genetic rat models of 
hypertension, compared to rats made hypertensive by renovascular surgery and endocrine 
manipulation (Pinto et al., 1998; Lerman et al., 2005). Gene knock out mouse models 
have been developed to study different aspects that contribute to metabolic disorders 
(Yang et al., 1999; Tsutsui et al., 2006). In our study we used two established rat models 
of hypertension, namely the genetic model of SHR and the other one is chemically 
induced hypertensive model by chronic treatment with the NOS inhibitor, L-NAME.  
Both these models share important characteristics that are similar to human essential 
hypertension (Lerman et al., 2005).  
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2.3.1.1. Spontaneously hypertensive rat (SHR) 
For experimental hypertension research, SHR model serves as an ideal and 
important animal model since it shares some of the structural modification seen in the 
vasculature with increased sympathetic activity that is seen in human essential 
hypertension. They are developed from the outbred normotensive (WKY) rats that were 
bred with selective hypertensive female WKY rats of the same group (Okamoto et al., 
1963). The WKY rat serves as a legitimate control wild type for SHR since the SHR 
strain was developed from cross mating with siblings with a wide selection from outbred 
WKY rat. As SHR age, they develop impairment in cardiac function. It is associated with 
increased coronary vascular resistance and reduced coronary flow reserve and 
impairment in renal functions that includes glomerular sclerosis, protenuria, glomerular 
fibrosis and glomerular hypertension (Zhou et al., 2007). There are studies demonstrating 
increased stiffness and decreased elasticity of the arterial wall in SHR which is also 
encountered in human essential hypertension (Marque et al., 1999; Bussy et al., 2000). 
Increased level of oxidative stress with reduced NO availability is another feature seen in 
the SHR model which is also a common feature in human essential hypertension (Zhou et 
al., 2008). Due to the impairment in structural and functional integrity of kidney as well 
as heart with high sympathetic out flow, this contributes to end organ damage associated 
with high BP in SHR. Alteration in physiological function with structural modification of 
the vasculature may contribute to progressive increases in vascular resistance and 
elevated BP which we normally see in human essential hypertension. Due to these 
similarities, SHR model is widely considered as a suitable experimental animal model for 
hypertension. 
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2.3.1.2. Chronic NOS inhibited hypertensive rat 
 Chronic NOS inhibition by treatment with NOS inhibitor, NG-nitro-L-arginine 
methyl ester (L-NAME), in drinking water for five days elevates MAP (Ribeiro et al., 
1992; Shinde et al., 2005, Desai et al., 2006). In the absence of NO, there is an 
overactivation of vasoactive contractile factors which are collectively responsible for the 
increase in vascular resistance and subsequent elevation in MAP. Chronic L-NAME 
treatment upregulates EDHF activity in rat models (Desai et al., 2006). The 
pathophysiological alterations that contribute to the impaired function of the heart with 
wide spread vascular resistance seen in human essential hypertension are exhibited by 
NOS inhibited hypertensive rats (Lahera et al., 1992). Lahera et al also reported that 
volume dependent hypertension probably occurs prior to renal impairment in NOS 
inhibited rat which is one of the cardinal features of human primary hyperetension 
(Lahera et al., 1992; Guyton et al, 1987). This NOS inhibited hypertensive rat model is a 
useful tool to evaluate the effects of amino acids in hypertensive rats. Again, it is very 
convenient, cheaper and less time consuming to develop NOS inhibited hypertensive rats 
than SHR.  
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CHAPTER 3. METHODS 
 
3.1. Animals 
 The present study was approved by our University Review Committee and the 
protocol conformed to the Guide for the Care and Use of Laboratory Animals stipulated 
by the Canadian Council on Animal Care and the National Institute of Health (NIH) 
publication No. 85-23. Two different strains of normotensive rats are used in the present 
study for comparison. They are 14 week old male Sprague-Dawley (SD) rats (300-350g) 
and WKY rats (280-320g). Two different models of hypertensive rats are used for the 
experimental protocol; 14 week old male WKY rats rendered hypertensive by 
pretreatment with NG nitro L-arginine methyl ester (L-NAME, 0.7 mg/mL in drinking 
water ad libitum) for 5 days and SHR (250-270g). All rats were obtained from Charles 
River (St. Constant, Quebec, Canada). 
   
3.2. Materials  
 Materials used in the present study are listed as follows: Fluorescent 
microspheres, glycine, Tween 20, Tween 80, potassium hydroxide (KOH), heparinized 
saline, saline, cellosolve, phenylephrine hydrochloride (PE), acetylcholine (ACh), NG 
nitro L-arginine methyl ester (L-NAME), (+)-5methyl-10,11-dihydro-5H-
dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801), memantine and sarcosine. 
Microspheres were obtained from Invitrogen, Inc, (Eugene, Oregon, U.S.A.). All other 
chemicals were obtained from Sigma-Aldrich Canada Ltd. (Oakville, ON., Canada). 
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Thiopental sodium was obtained from Abbott Laboratories Ltd (Saint Laurent, Quebec, 
Canada).  
  
3.3. Experimental procedures 
 The regional hemodynamic studies as well as in vivo experiments were conducted 
in anesthetized rats. All rats were allowed to fast over night. In vitro studies were carried 
out using aortic rings isolated from the same rat strains.  
 
3.3.1. Regional hemodynamic study 
 
3.3.1.1. Surgical procedure for regional hemodynamic study 
 Rats were anesthetized with i.v. thiopental sodium (100 mg/kg, body weight) and 
body temperature was maintained 37 0C by putting the rat on an electrical heating pad 
throughout the surgery period. All the rats were allowed to breathe spontaneously with 
the insertion of a tracheal tube. The right femoral artery of each rat was cannulated with 
PE-50 tubing which was then connected to a pressure transducer to measure the MAP and 
HR using a Power Lab data acquisition system (AD Instruments Inc., Sydney, Australia).  
The left femoral artery was cannulated with PE-50 tubing and connected to a reciprocal 
syringe pump (Harvard Apparatus, Quebec, Canada) for collecting reference blood 
sample during microsphere injection. The left femoral vein was also cannulated with poly 
ethylene tubing (PE 50) and was used for bolus injection (0.4 ml/kg) of either vehicle 
(saline) or glycine (prepared in saline and pH was maintained to 7.3 for all the 
experiments). The final surgical procedure involved the cannulation of right carotid with 
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PE-50 through the common carotid to the left ventricle. The proper position of the 
cannula was confirmed with a typical ventricular wave-form (Glenny et al., 1993; 
Gervais et al., 1999). 
 
3.3.1.2. Measurement of hemodynamic changes using fluorescent microspheres 
 Blood flow to different organs was measured by using a perfused fluorescent 
microsphere distribution technique. Four different colors (green, red, red-orange and 
carmine) of 15 μm diameter fluorescent microspheres (Fluo Spheres®) were purchased 
and stored at 4 0C. The colors of microspheres used in a single study were paired on the 
basis of their absorption/emission maxima wavelength (nm) in order to avoid spill over. 
Before administration, the microspheres were sonnicated and vortexed heavily to avoid 
sedimentation. Then it was diluted to a final volume of 0.3 ml with the addition of 0.9 % 
saline containing 0.01 % w/v Tween 20. This diluted microsphere solution was again 
vortexed and immediately injected into the left ventricle through the carotid cannula over 
a period of 20 seconds at the same time when saline/glycine was injected through the left 
femoral vein. Then the carotid cannula was flushed with saline over a period of 80 
seconds to make sure no microsphere was left in the carotid artery. Withdrawal pump 
(0.5 ml/min) was started 10 seconds before the injection of microspheres/saline to collect 
reference blood samples for 80 seconds from the femoral artery. Immediately the 
reference blood sample was transferred to a 10 ml glass tube containing an anticoagulant 
heparin and placed on ice. The same procedure was followed to collect reference blood 
samples when glycine (1.0 mmol/kg) was injected through the femoral vein. Different 
microspheres were used for saline, glycine and MK-801. Then the animal was euthanized 
 56 
with a high dose of thiopental sodium. Heart, kidneys, spleen, lungs, pancreas and brain 
were collected as whole and tissues from liver, small intestine, large intestine, skeletal 
muscle and diaphragm were also collected and placed in cold saline. All tissues were 
patted dry, transferred to 10 ml glass tubes and weighed. The reference blood samples 
and tissues were digested in 3-4 ml of ethanolic potassium hydroxide (4.0 M) solution per 
gram of tissue for 24-48 hours. The tubes were shaken thoroughly every few hours. After 
48 hours, the microspheres were recovered by centrifuging at 2000 x g (Precision, 
Durafuge 100, Winchester, VA) for 20 minutes. Supernatants were carefully removed 
leaving < 1 ml. The pellet with microspheres was rinsed with 9 ml of 0.25 % Tween 80 in 
demineralized water at 60 0C, vortexed, centrifuged again at 2000 x g for 20 min. A final 
rinse with demineralized water without Tween 80 was carried out and the supernatant 
was carefully removed leaving <1 ml. To extract dye, 3 ml of cellosolve acetate (2-
ethoxy-ethyl acetate) was added to each tube, vortexed thoroughly, wrapped with 
aluminum foil and allowed to stand for 4 hours to dissolve the microspheres, which were 
then vortexed and centrifuged again at 2,000 x g for 15 minutes. The supernatant was 
carefully removed and used for measurement of fluorescence intensity. 
  
3.3.1.3. Measurement of fluorescence 
 F-2500 fluorescence spectrometer (Hitachi, Tokyo, Japan) was used to measure 
fluorescence intensity at excitation and emission wavelengths between 350-750 nm using 
5 nm slit width. Each individual sample was read in a 5 ml quartz cuvette in duplicate. To 
determine the blood flow rate per tissue sample (ml/min/g), the following formula was 
used: Fi = (Ii)(R)/Iref where: Fi = flow to individual sample (ml/min), Ii = fluorescence 
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intensity of the sample, R = reference sample withdrawal rate (ml/min), Iref = 
fluorescence intensity of the reference blood sample. MAP (mmHg), HR (beats/min), 
CO=Total no. of injected microspheres x reference rate (0.5 ml/min) ÷ no. of 
microspheres in the reference blood sample, TPR (mmHg/ml/min) were calculated 
(Sampaio et al., 2003, Giancarla et al., 2007). 
 
3.2.2. In vivo studies 
 For in vivo study, we used SHR and age matched normotensive Sprague-Dawley 
(SD), WKY, and WKY rats rendered hypertensive by treatment with NOS inhibitor L-
NAME (0.7 mg/mL in drinking water ad libitum) for 5 days that serves as an additional 
hypertensive model. Rats were anesthetized with i.v. thiopental sodium (100 mg/kg, body 
weight) and body temperature was maintained 37 0C by putting the rat on an electrical 
heating pad throughout the experiment. All the rats were allowed to breathe 
spontaneously through a tracheal cannula. The right femoral artery of each rat was 
cannulated with PE 50 tubing which was then connected to a pressure transducer to 
measure the MAP and HR using a Power Lab data acquisition system (AD Instruments 
Inc., Sydney, Australia). Either left or right femoral vein was cannulated for vehicle and 
drug administration during the experiment. Volume of vehicle and every dose of drug 
administered were limited to a volume of 0.4 mL/kg body weight. The pH of all the drugs 
that were administered was adjusted to 7.3 in all the experiments. A few minutes after 
cannulation, once the MAP and HR became stabilized, i.v. administration of different 
doses of drug were started. Sufficient time was given between every dose to make sure 
that the baseline comes back to the resting level. Once the MAP came back to the resting 
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baseline, the second dose was administered. Saline was used as the vehicle for these 
experiments. Glycine, MK-801, memantine and sarcosine were dissolved in saline. Bolus 
i.v. administration of vehicle was followed by administration of glycine (1.0 mmol/kg) in 
all the four rat models. Then, NMDA antagonists, either MK-801 (75 mg/kg), or 
memantine (50 mg/kg) was slowly infused through i.p. injection over a period of 10 to15 
min in these rat models (Deng et al., 2002; Rammes et al., 2008). Subsequently 30 min 
after infusion of MK-801 and 15 min after the infusion of memantine, the responses to 
glycine was determined. Similarly glycine (1.0 mmol/kg) mediated responses were 
determined before and 10 min after the slow infusion of the glycine transporter inhibitor, 
sarcosine (100 mg/kg, i.p.) given over a period of 10 min to all groups of rats.  
 
3.3.3. In vitro studies 
 Male WKY rats (300-350 gm) and SHR (250-270 gm) were anesthetized with 
thiopental sodium (100 mg/kg, i.v.) and the thoracic aorta was isolated and placed in cold 
Kreb’s Henseleit buffer. The composition of Kreb’s Henseleit buffer (mM) was: 118 
NaCl, 4.7 KCl, 1.2 MgCl2.5H2O, 1.8 CaCl2.2H2O, 1.2 KH2PO4, 25 NaHCO3, 5.5 Glucose. 
The aorta was cleaned for surrounding fat and mounted in organ bath chamber containing 
Kreb’s solution maintained at 37 0C with a constant supply of carbogen, which contains 
95% oxygen and 5% carbon dioxide. Resting tension (2 gm) was fixed for initial 
equilibration period of 1 h in Kreb’s buffer.  After a 60 min wash period, the aortic rings 
were normalized using standard procedures (bridge amplifier zero). Subsequently the 
aortic rings were contracted with PE (1 µmol/L). Relaxation of PE constricted vessels to 
ACh (10 µmol/L) was used to determine endothelial integrity. The endothelium was 
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considered as denuded if there was no vasodilator response to the addition of a fixed 
concentration of ACh (10 μmol/L) in the PE constricted vessels. Then, relaxation of PE 
constricted vessels to glycine (0.1 to 3.0 mmol/L) was examined. The vasodilator 
responses of glycine (0.1 to 3.0 mmol/L) were determined both in endothelium intact and 
endothelium denuded vessels of normotensive WKY rats. After a period of 60 min wash, 
aortic rings were incubated with nitric oxide synthase inhibitor, L-NAME (100 µmol/L) 
and NMDA receptor antagonist MK-801 (10 µmol/L) separately and the responses to 
glycine were determined in endothelium intact vessels in WKY rats. Similar procedures 
were followed to determine the effect of glycine on aortic rings isolated from SHR. 
 
3.4. Statistical analysis  
 The vasodilator responses were calculated as a percent of each tissue’s response 
to a fixed concentration of PE. Concentration response (CR) curves were computer fitted 
to nonlinear curve fit (Graph Pad Prism, Graph Pad Software Inc). Maximum relaxation 
attained after each dose was used to plot the dose-response curve to glycine.  Relaxations 
are expressed as percentage reversal of PE induced tone. All data are shown as mean ± 
SEM. Then (n = 6) values quoted similarly indicate the number of animals used. 
Differences of means, between two groups were calculated by student’s t-test. In all cases 
differences were considered significant when P < 0.05. 
 
The change in MAP, HR, CO and  TPR following glycine administration were plotted as 
bar diagrams and the data are expressed as mean ± SEM (n = 6). The changes in MAP 
during glycine administration both in presence and absence of NMDA antagonists were 
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also plotted and the significance levels of the differences between means were calculated. 
Changes in MAP during glycine administration before and after the infusion of sarcosine 
were also determined. Differences of means, between more than two groups were 
calculated by one way analysis of variance followed by Tukey’s post hoc test. The 
differences were considered significant when P < 0.05. 
 
Changes in organ blood flow and organ vascular resistance during glycine administration 
were calculated and the data are expressed as mean ± SEM (n = 6). The differences 
between means were calculated by one way analysis of variance followed by Tukey’s 
post hoc test. The differences between means were considered significant when P < 0.05. 
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CHAPTER 4. RESULTS 
 
4.1. Regional hemodynamic study 
 
4.1.1. Comparison of basal systemic hemodynamic parameters between 
normotensive Sprague-Dawley rats vs. WKY rats 
Data pooled from several experiments show that there are no significant 
differences in systemic hemodynamic parameters such as MAP (112 ± 2 mmHg, 116 ± 5 
mmHg), HR (366 ± 5 bpm, 364 ± 9 bpm),  CO (108 ± 5 ml/min/gm, 106 ± 5 ml/min/gm), 
and TPR (1.05 ± 0.2 mmHg/ml/min, 1.09 ± 0.08 mmHg/ml/min) values determined in 
two groups of age-matched male Sprague-Dawley rats and WKY rats (n = 6 per each 
group) respectively (Table 3). 
 
4.1.2. Normotensive WKY rats vs. hypertensive rat models 
The basal MAP values were significantly higher (P < 0.01) in both L-NAME 
treated WKY rats (158 ± 3 mmHg) and SHR (183 ± 7 mmHg) compared to values 
determined in WKY (116 ± 5 mmHg) group (Figure 2, and Table 3). A significant 
decrease (P < 0.01) in CO (77 ± 3 ml/min/gm) was noted in L-NAME treated WKY 
compared to CO values in normotensive WKY rats (106 ± 5 ml/min/gm) (Figure 3, and 
Table 3). This pattern of increase (P < 0.01) in MAP and decrease (P < 0.05) in CO was 
also significant in the genetic model of SHR strain, (83 ± 2 ml/min/gm) compared to CO 
values noted in normotensive WKY (106 ± 5 ml/min/gm) group (Figure 3, and Table 3).  
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However, the HR values were significantly higher (P < 0.05) in SHR (383 ± 6 bpm) 
group compared to WKY (363 ± 9 bpm) group (Figure 4 and Table 3). The HR values 
were not significantly different between L-NAME treated WKY (349 ± 8 bpm) and 
WKY (363 ± 9 bpm) group (Figure 4 and Table 3).  
 
4.1.3. L-NAME treated WKY rats vs. SHR 
A significant difference (P < 0.01) in HR values was noted between L-NAME 
treated WKY (349 ± 8 bpm) and SHR (383 ± 6 bpm) group (Figure 4 and Table 3). 
Moreover, the MAP was much higher (P < 0.05) in SHR (183 ± 7mmHg) compared to 
MAP (158 ± 3 mmHg) values seen in L- NAME treated WKY group (Figure 2 and Table 
3). 
4.2. Comparison of glycine induced changes in systemic parameters  
 
4.2.1. Normotensive Sprague-Dawley rats vs. WKY rats  
 Data pooled from several experiments show that there was no significant 
differences in systemic hemodynamic parameters, such as MAP (79 ± 6 mmHg vs. 76 ± 8 
mmHg), HR (378 ± 4 bpm vs. 386 ± 7 bpm), CO (125 ± 6 ml/min/gm vs. 126 ± 5 
ml/min/gm) and TPR (0.5 ± 0.07 mmHg/ml/min vs. 0.6 ± 0.04 mmHg/ml/min) between 
the two normotensive groups, Sprague-Dawley and WKY rats respectively, following 
acute glycine (1 mmol/kg) administration (Table 3). 
 
4.2.2. Normotensive WKY rats vs. hypertensive rat models 
Acute i.v. glycine administration led to significant changes in several 
hemodynamic parameters in both normotensive WKY and L-NAME treated WKY and 
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SHR strains. MAP (76 ± 8 mmHg) decreased (P < 0.01) and CO (126 ± 5 ml/min/g) 
increased significantly (P < 0.01) in WKY rats compared to basal MAP (116 ± 5 mmHg) 
and CO (106 ± 5 ml/min/g) values noted prior to glycine administration (Figure 5, Figure 
6, and Table 3). However, there was no significant difference in HR values before (363 ± 
9 bpm) and after (386 ± 9 bpm) glycine administration in WKY rats (Figure 7). However, 
TPR (0.6 ± 0.04 mmHg/ml/min) decreased significantly (P < 0.05) during glycine 
administration compared to TPR (1.09 ± 0.08 mmHg/ml/min) during vehicle 
administration (Table 3).  
 
In hypertensive L-NAME treated rats, there was a significant increase (P < 0.05) in MAP 
(182 ± 6 mmHg) and decrease (P < 0.05) in CO (64 ± 3 ml/min/gm) following acute 
glycine administration, compared to MAP (158 ± 3 mmHg) and CO (77 ± 3 ml/min/gm) 
following vehicle administration while there was no significant change (349 ± 9 bpm vs 
334 ± 9 bpm) in HR (Figure 5, Figure 6, Figure 7, and Table 3). TPR (2.8 ± 0.19 
mmHg/ml/min) increased significantly (P < 0.01) with glycine administration compared 
to the baseline TPR (2.05 ± 0.16 mmHg/ml/min), following vehicle administration, in L-
NAME treated WKY rats (Table 3). The saline administration (vehicle) did not evoke 
any significant change from baseline parameters for MAP, CO, HR, and TPR while 
differences were remarkable following glycine administration. 
 
In SHR group, the basal MAP was higher (210 ± 6 mmHg) and CO was lower (63 ± 3 
ml/min/gm), compared to the baseline MAP (183 ± 7 mmHg) and CO (83 ± 2 
ml/min/gm). The differences in MAP (P < 0.05) and CO (P < 0.05) were statistically 
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significant (Figure 5, Figure 6, and Table 3). HR did not show any significant change 
(383 ± 6 bpm vs. 360 ± 6 bpm) in SHR following glycine administration compared to 
vehicle administration (Figure 7 and Table 3). The TPR (3.3 ± 0.24 mmHg/ml/min) 
increased significantly (P < 0.01) following acute glycine administration, compared to 
the resting TPR (2.2 ±0.11 mmHg/ml/min) values noted in the same group of rats (Table 
3). 
 
4.2.3. L-NAME treated WKY rats vs. SHR  
No significant change was observed in systemic hemodynamic parameters such as 
MAP (182 ± 6 mmHg vs. 210 ± 6 mmHg), HR (334 ± 9 bpm vs. 360 ± 6 bpm), CO (64 ± 
3 ml/min/gm vs. 63 ± 3 ml/min/gm) and TPR (2.8 ± 0.19 mmHg/ml/min vs. 3.3 ± 0.24 
mmHg/ml/min) between the two hypertensive rat models, L-NAME treated hypertensive 
WKY and SHR following acute glycine administration (Table 3). 
 
4.3. Comparison of regional blood flow between normotensive WKY rats vs. 
hypertensive rat models 
 We found a significant fall in MAP during glycine (1 mmol/kg) administration 
compared to vehicle administration in normotensive WKY rats (Figure 8A). This fall in 
MAP was blocked in the presence of MK-801 (Figure 8 A). However in L-NAME treated 
WKY group glycine evoked increase in MAP was blocked in the presence of MK-801 
(Figure 8 B). Similarly, in hypertensive SHR strain glycine did not increase MAP 45 min 
after the incubation of MK-801 (Figure 8 C). Data pooled from several experiments 
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revealed that there were significant changes in the blood flow values between 
normotensive and hypertensive rats during saline/glycine administration (Table 4). 
 
4.3.1. Comparison of basal blood flow - WKY rats vs. hypertensive rat models 
A significant difference in basal blood flow to different organs/tissues in 
hypertensive rats was noted in comparison to normotensive WKY rats. Acute vehicle 
administration (saline, 0.4 mL/kg) per se did not modify the basal blood flow to various 
organs/tissues occurred in the following rank order with the highest level of blood flow to 
kidneys; kidneys> heart> brain> pancreas> diaphragm> small intestine> large intestine> 
stomach> spleen> skeletal muscle (Table 4). The baseline blood flow to either kidney 
was similar with a difference of < 5% in all the three rat models. In WKY rats, the 
kidneys received the highest blood flow, followed by heart and brain (Table 4). In L-
NAME treated WKY, the basal blood flow calculated was highest in kidneys> heart> 
brain> diaphragm> spleen> stomach> small intestine> pancreas> skeletal muscle> large 
intestine (Table 4). In SHR, the basal blood flow was highest in the following rank order 
heart> kidney> brain> skeletal muscle> small intestine> pancreas> stomach> large 
intestine> diaphragm (Table 4). In SHR strain, the basal blood flow to kidneys was much 
less compared to the basal blood flow to kidneys in WKY rats, and the difference is 
significant (P < 0.001, Table 4).  
  
4.3.2. Comparison of basal blood flow - L-NAME treated WKY rats vs. SHR 
In SHR, there was a significant decrease in blood flow to kidneys when compared 
to the blood flow in L-NAME treated hypertensive WKY rats and the difference in values 
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between these two strains was significant (P < 0.001) (Table 4). Blood flow to spleen was 
also significantly lower (P < 0.05) in SHR compared to the blood flow to spleen in L-
NAME treated WKY rats (Table 4). 
 
4.4. Comparison of glycine induced changes in regional blood flow 
 
4.4.1. Normotensive WKY rats vs. hypertensive rat models 
A significant change in blood flow to most vital organs were noted following 
acute glycine (1 mmol/kg) administration among and between normotensive as well as 
hypertensive rat models. In normotensive WKY rats, there was a significant increase in 
blood flow to kidneys, heart and brain after glycine administration compared to acute 
vehicle administration (Figure 9 A and Table 4). Acute administration of glycine 
increased blood flow to left vs. right kidneys, (188%) and (192%) respectively compared 
to vehicle in WKY rats. The differences of means were significant (P < 0.01, Figure 9 A, 
Table 4). We observed an increase in blood flow to heart (160%), after glycine 
administration compared to baseline blood flow to heart and the difference was 
significant (P < 0.05, Figure 9 A, Table 4). Blood flow to brain was also increased (59%), 
following glycine administration compared to vehicle administration, and this increase is 
significant (P < 0.05, Figure 9 A and Table 4). We did not find any significant change in 
blood flow to pancreas, diaphragm, skeletal muscle, spleen, stomach, small intestine and 
large intestine following glycine administration, compared to vehicle administration 
(Figure 9 A, Figure 9 B and Table 4). 
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In L-NAME treated WKY rats glycine evoked a significant decrease (P < 0.01) in blood 
flow to kidneys (46%) and (47%), heart (46%) and brain (35%) compared to blood flow 
following vehicle administration in the same organs (Figure 10 A, Table 4).  Blood flow 
to pancreas (61%) and diaphragm (33%) were also significantly decreased (P < 0.05) 
compared to blood flow following vehicle administration in pancreas and diaphragm 
(Figure 10 A and Table 4). However, acute glycine administration did not alter the blood 
flow to the following organs, such as skeletal muscle, spleen, stomach, small intestine 
and large intestine compared to vehicle administration (Fig. 10 A and Table 4).  
 
In SHR, acute glycine administration significantly decreased (P < 0.05) blood flow to 
kidneys left vs. right, (51%) and (57%) respectively, heart (71%), brain (55%), pancreas 
(47%) and skeletal muscle (57%) compared to vehicle administration in the same organs 
(Figure 11 A and Table 4). Blood flow to following organs/tissues such as, diaphragm, 
spleen, stomach, small intestine and large intestine were not significantly different after 
glycine administration compared to vehicle administration (Figure 11 B and Table 4). 
While acute glycine administration decreased the blood flow to several vital organs, its 
effect on changes in blood flow in splanchnic vascular beds was not significant. 
  
4.4.2. L-NAME treated WKY rats vs. SHR 
 In L-NAME treated WKY rats, administration of glycine significantly decreased 
blood flow (P < 0.05) to diaphragm compared to vehicle administration whereas, in the 
SHR group glycine significantly decreased blood flow (P < 0.05) to skeletal muscle 
compared to vehicle (Table 4). 
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4.5. Changes in regional blood flow before and after glycine administration in 
presence of MK-801 
In normotensive WKY rats glycine induced fall in MAP and in hypertensive L-
NAME treated WKY rats and SHR strain glycine induced increase in MAP were blocked 
in the presence of NMDA antagonist MK-801 (Figure 12 A, B, C). This increase and 
decrease in MAP were associated with increase and decrease in blood flow to different 
vascular beds in these rat models. In the normotensive WKY rats acute glycine 
administration increased blood flow to vital organs such as heart, kidney and brain 
compared to vehicle administration whereas in presence of MK-801 the same dose of 
glycine did not produce any significant change in blood flow to the same organs (Figure 
13 A). Glycine did not show any significant difference in blood flow to stomach, small 
intestine, large intestine and spleen in the presence of MK-801 in WKY rats (Figure 13 
B). In L-NAME treated WKY glycine decreased the blood flow to heart, kidneys, brain, 
pancreas and diaphragm (Figure 14 A). This response was blocked in the presence of 
MK-801 (Figure 14 A). Glycine did not any significant change in blood flow to stomach, 
small intestine, large intestine and spleen either in the presence or absence of MK-801 in 
L-NAME treated rats (Figure 14 B).  Similarly, in SHR glycine mediated decrease in 
blood flow to heart, kidneys, brain, pancreas and skeletal muscle were blocked 
completely in presence of MK-801(Figure 15 A). In the splanchnic vascular bed glycine 
did not show any significant change in the blood flow both in the presence or absence of 
MK-801 compared to blood flow during saline administration in SHR strain (Figure 15 
B). This result provides an important information that MK-801, a non selective NMDA 
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receptor antagonist completely blocked glycine mediated increase and decrease in blood 
flow to several organs/tissues in normotensive WKY rats and hypertensive rat models.  
 
4.6. Comparison of basal organ vascular resistance 
Since there was wide variation observed in basal regional blood flow to various 
organs/tissues in all strains, we calculated the baseline organ vascular resistance values, a 
measurement that is inversely associated with blood flow. The values calculated varied 
significantly in normotensive WKY rats, L-NAME treated hypertensive WKY rats and 
SHR groups (Table 5). 
 
4.6.1. Normotensive WKY rats vs. hypertensive rat models 
Data gathered from several experiments revealed that in hypertensive rat models 
basal peripheral organ vascular resistance was elevated in some organs/tissues compared 
to normotensive WKY rats. In L-NAME treated hypertensive WKY rats organ vascular 
resistance increased significantly in different organs/tissues in following rank order (P < 
0.001) in large intestine,  (P < 0.01) in pancreas, (P < 0.05) in spleen compared to 
normotensive WKY rats (Table 5). Whereas organ vascular resistance significantly 
decreased (P < 0.001) in diaphragm and (P < 0.05) in brain compared to normotensive 
WKY rats (Table 5). Interestingly, in SHR group, the overall organ vascular resistance 
was found to be higher than L-NAME treated hypertensive rats and increased 
significantly to the following organs/tissues (P < 0.001) such as,  kidneys, (P < 0.001) 
spleen, (P < 0.01) pancreas, (P < 0.01) small intestine  and (P < 0.05) heart compared to 
normotensive WKY group (Table 5).  
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4.6.2. L-NAME pretreated hypertensive WKY rats vs. SHR 
Although we found an increase in organ vascular resistance in both L-NAME 
pretreated hypertensive WKY and SHR strain, clearly overall vascular resistance was 
found to be higher in many organs/tissues in SHR compared to L-NAME treated 
hypertensive WKY rats (Table 5). In SHR, there is an wide spread increase in organ 
vascular resistance to following organs/tissues (P < 0.01) in kidneys, (P < 0.01) in spleen, 
(P < 0.05) in diaphragm, compared to L-NAME pretreated hypertensive WKY group 
(Table 5).  
 
4.7. Glycine Induced changes in organ vascular resistance 
 
4.7.1. Normotensive WKY rats vs. hypertensive rats 
Following glycine administration, in normotensive WKY rats organ vascular 
resistance decreased significantly (P < 0.001) in heart, kidneys, brain and diaphragm 
compared to the vascular resistance seen in the same organs after vehicle administration 
(Table 5). However, in both the hypertensive rat models, the organ vascular resistance 
increased significantly following acute glycine administration compared to vehicle 
administration. In L-NAME treated WKY rats, glycine administration evoked an increase 
(P < 0.001) in the vascular resistance in brain, pancreas, diaphragm, (P < 0.01) kidneys, 
and (P < 0.05) heart compared to vehical administration in the respective organs (Table 
5). Alternately, in SHR strain, vascular resistance increased significantly (P < 0.001) in 
heart, kidneys, brain, diaphragm, skeletal muscle and (P < 0.01) pancreas following 
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glycine administration compared to vehicle administration in the same group of rats 
(Table 5).  
 
4.7.2. L-NAME pretreated hypertensive WKY rats vs. SHR 
Organ vascular resistance is significantly higher in hypertensive rat models. 
However, increases in resistance in individual organs/tissues are not similar between L-
NAME treated WKY and SHR groups (Table 5). Glycine-evoked increase in vascular 
resistance in hypertensive rat models targets several different organs, although some of 
them are common. In L-NAME treated hypertensive rats glycine targets following 
organs/tissues where the vascular resistance values are significantly higher (P < 0.001) in 
pancreas, (P < 0.05) brain, heart and diaphragm compared to SHR strain (Table 5). 
However, in SHR, vascular resistance values are found to be significantly higher (P < 
0.05) in kidneys compared to L-NAME treated group (Table 5). In addition, skeletal 
muscle vascular resistance was increased significantly (P < 0.001) after glycine 
administration in SHR but not in chronic L-NAME treated WKY (Table 5). 
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Figure 2. The bar diagram compares the basal MAP (mmHg) levels in 14 week old male 
WKY, chronic L-NAME (L-N) treated WKY and SHR strains. Each bar represents mean 
± SEM values (n = 6 rats/group).  
**p < 0.01 compared to WKY group.  
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Figure 3. The bar diagram compares the basal cardiac output (ml/min) in14 week old 
WKY, chronic L-NAME treated WKY (L-N) and SHR strains.  Each bar represents mean 
± SEM values (n = 6 rats/group). 
 *p < 0.05 and **p < 0.01 compared to WKY group.  
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Figure 4. The bar diagram compares the basal heart rate values (beats/min) in 14 week 
old WKY, chronic L-NAME treated WKY and SHR strains. Each bar represents mean ± 
SEM values (n = 6 rats/group).  
*p < 0.05 compared to WKY group.  
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Figure 5. The bar diagram compares the MAP (mmHg) before and after acute glycine 
administration (1.0 mmol/kg, i.v.) in 14 week old WKY, chronic L-NAME treated WKY 
(L-N) and SHR strains. Each bar represents mean ± SEM values (n = 6 rats/group).  
*p < 0.05 compared to respective control group.  
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Figure 6. The bar diagram compares the cardiac output before and after acute glycine 
administration (1.0 mmol/kg, i.v.) 14 week old WKY, chronic L-NAME (L-N) treated 
WKY and SHR strains. Each bar represents mean ± SEM values (n = 6 rats/group).  
*p < 0.05, **p < 0.01 compared to respective control group.  
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Figure 7. The bar diagram compares the HR before and after acute glycine 
administration (1.0 mmol/kg, i.v.) in 14 week old WKY, chronic L-NAME (L-N) treated 
WKY and SHR strains. Each bar represents mean ± SEM values (n = 6 rats/group).  
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Figure 8 A. A typical representative experiment that shows the fall in MAP to acute 
administration of glycine before and after slow infusion of MK-801 (75 mg/kg, i.p.). MK-
801 blocks glycine evoked response 45 minute after its intraperitonial administration in 
normotensive WKY rats (n = 6 rats). 
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Figure 8 B. A typical representative experiment that shows acute glycine (1 mmol/kg) 
administration elevates MAP and MK-801 (75 mg/kg, i.p.) blocks the response in chronic 
L-NAME treated WKY rats (n = 6 rats).  
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Figure 8 C. A typical representative experiment that compares the increase in MAP 
following acute glycine administration (1.0 mmol/kg, i.v.) and lack of pressor response to 
same dose of glycine after administration of  MK-801 (75 mg/kg, i.p.) in SHR strains (n 
= 7 rats). 
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Figure 9 A. Comparison of blood flow to different organs/tissues (heart, left kidney, right 
kidney, brain, pancreas, skeletal muscle and diaphragm) following acute glycine (1.0 
mmol/kg, i.v) administration in 14 week old WKY rats. Each bar represents mean ± SEM 
values (n = 6 rats).  
*p < 0.05, **p < 0.01 compared to respective control value.  
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Figure 9 B. Comparison of regional blood flow (ml/min/gm) to different organs/tissues 
(spleen, stomach, small intestine and large intestine) following acute glycine (1.0 
mmol/kg, i.v) administration in 14 week old WKY rats. Each bar represents mean ± SEM 
value (n = 6 rats).   
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Figure 10 A. Comparison of regional blood flow (ml/min/gm)  to different organs/tissues 
(heart, left kidney, right kidney, brain, pancreas, diaphragm and skeletal muscle) 
following acute glycine administration (1.0 mmol/kg, i.v) in 14 week old chronic L-
NAME (L-N) treated WKY rats. Each bar represents mean ± SEM value (n = 6 rats).  
*p < 0.05, **p < 0.01 compared to respective control.  
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Figure 10 B. Comparison of regional blood flow to different organs/tissues (spleen, 
stomach, small intestine and large intestine) after acute glycine administration (1.0 
mmol/kg, i.v.) in 14 week old chronic L-NAME treated WKY rats. Each bar represents 
mean ± SEM value (n = 6 rats).  
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 Figure 11 A. Comparison of the regional blood flow (ml/min/gm) to different 
organs/tissues (heart, left kidney, right kidney, brain, pancreas, skeletal muscle and 
diaphragm) following acute glycine infusion (1.0 mmol/kg, i.v.) in 14 week old SHR. 
Each bar represents mean ± SEM value (n = 6 rats).  
*p < 0.05 compared to respective control.   
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Figure 11 B. Comparison of the regional blood flow (ml/min/gm) to following tissues 
(spleen, stomach, small intestine and large intestine) after acute glycine administration 
(1.0 mmol/kg, i.v.) in 14 week old SHR. Each bar represents mean ± SEM value (n = 6 
rats).  
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Figure 12.  The dose-response curves compare MAP (mmHg) evoked by increasing 
concentration of glycine (0.3 to 3.0 mmol/kg), either before () and after (●) slow 
infusion of MK-801(75 mg/kg, i.p)  administration in WKY (A), chronic L-NAME 
treated WKY (B) and SHR (C) strains.  Each data point is mean ± SEM values (n = 6 
rats/group).  
*p < 0.05, **p < 0.01 compared to respective control in each group.  
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Figure 13 A. Bar diagram compares the blood flow (ml/min/gm) attained in various 
tissues/organs (heart, left kidney, right kidney, brain) following either vehicle 
administration (saline, i.v. control) or acute glycine administration (1.0 mmol/kg, i.v.) 
before and   after infusion of NMDA antagonist, MK-801(75 mg/kg, i.p.) over a 45 min 
period in 14 week old WKY rats.  
 *p< 0.05, **p < 0.01 compared to respective control (n = 6 rats).    
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Figure 13 B. The bar diagrams give the level of blood flow (ml/min/gm) in various 
tissues/organs (spleen, stomach, small intestine, large intestine) following either acute 
vehicle administration (saline, i.v. control) or acute glycine administration (1.0 mmol/kg, 
i.v.) before and   after administration of NMDA antagonist, MK-801(75 mg/kg, i.p.) over 
a 45 min period in 14 week old WKY rats. Each bar represents mean ± SEM value (n = 6 
rats).  
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Figure 14 A. The bar diagram compares the blood flow (ml/min/gm) values in the 
following organs/tissues (Heart, left kidney, right kidney, brain, pancreas, diaphragm) 
following either vehicle administration (saline, i.v. control) or glycine administration (1.0 
mmol/kg, i.v.) or glycine administration after MK-801 (75 mg/kg, i.p.) administration, 
over a period of 45 min in 14 week old chronic L-NAME (L-N) treated WKY rats. Each 
bar represents mean ± SEM value (n = 6 rats).  
*p < 0.05, **p < 0.01 compared to respective control. 
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Figure 14 B. The bar diagram compares the blood flow (ml/min/gm) values in the 
indicated organs/tissues (spleen, stomach, small intestine and large intestine), following 
either vehicle administration (saline, i.v. control) or acute glycine administration (1.0 
mmol/kg, i.v.) or glycine administration after slow infusion of MK-801 (75 mg/kg, i.p.) 
over a period of 45 min in 14 week old chronic L-NAME (L-N) treated WKY rats. Each 
bar represents mean ± SEM value (n = 6 rats).  
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Figure 15 A. The bar diagram compares the blood flow (ml/min/gm) values in the 
indicated organs/tissues (heart, left kidney, right kidney, brain, pancreas, skeletal 
muscle), following either vehicle administration (saline, i.v. control) or acute glycine 
administration (1.0 mmol/kg, i.v) or glycine administration after slow infusion of NMDA 
antagonigt, MK-801 (75 mg/kg, i.p.), over a period of 45 min in 14 week old SHR. Each 
bar represents mean ± SEM value (n = 6 rats).  
*p < 0.05 compared to respective control. 
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Figure 15 B. The bar diagram compares the blood flow (ml/min/gm) values in the 
indicated organs/tissues (spleen, stomach, small intestine and large intestine), following 
either vehicle administration (saline, i.v. control) or acute glycine administration (1.0 
mmol/kg, i.v.) or glycine administration after slow infusion of NMDA antagonigt, MK-
801 (75 mg/kg, i.p.), over a period of 45 min in 14 week old SHR. Each bar represents 
mean ± SEM value (n = 6 rats).  
 Table 3. Comparison of MAP (mmHg), heart rate (beats/min), cardiac output (ml/min) and total peripheral resistance (mmHg/ml/min) 
before and after acute i.v. glycine administration in 14 week old male WKY, L- NAME treated WKY and SHR strains. 
3.3±0.24**63±3*††360±6210±6*††2.2±0.11††83±2†383±6†‡183±7††SHR
2.8±0.19**64±3*††334±9182±6*††2.05±0.16††77±3††349±8     158±3††
L-NAME 
treated 
WKY
0.6±0.04*126±5**386±7      76±8**1.09±0.08106±5366±9    116±5WKY
0.5±0.07125±6378±479±61.05±0.2108±5366±5112±2SD
TPRCOHRMAPTPRCOHRMAP
GlycineBase lineStrain
          
      
      
     
                 
               
 
Each data is mean ± SEM values (n = 6 rats/group).  *p<0.05 and **p<0.01 compared to control group. 
 †p<0.05 and ††p<0.01 compared to control group.  ‡p<0.05 compared to L-NAME treated group. 
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 Table 4. Comparison of blood flow (ml/min/gm) attained in various organs/tissues following either vehicle administration (saline, i.v. 
control group) or glycine (1.0 mmol/kg, i.v.) administration in 14 week old WKY, L-NAME treated WKY and SHR strains.     
Strain WKY L-NAME treated WKY SHR 
Tissue Control Glycine Control Glycine Control Glycine 
  Blood flow (ml/min/g) 
Heart 2.897±0.279 4.647±0.301* 3.262±0.281 1.519±0.289** 3.369±0.213 2.406±0.215* 
Left Kidney 3.641±0.128 6.860±0.125** 3.759±0.267 1.765± 0.183** 1.827±0.055†††‡‡‡ 0.944±0.170* 
Right Kidney 3.584±0.141 6.888±0.131** 3.656±0.180 1.733±0.259** 1.858±0.048†††‡‡‡ 1.075±0.125* 
Brain 1.144±0.106 1.946±0.253* 1.579±0.266 0.567±0.161** 1.527±0.154 0.841±0.094* 
Pancreas 1.131±0.185 1.400±0.241 0.701±0.082 0.196±0.042* 0.900±0.129 0.426±0.132* 
Diaphragm 0.192±0.085 0.256±0.124 0.675±0.80 0.226±0.04 * 0.332±0.057 0.289±0.042 
Skeletal muscle 1.085±0.149 1.378±0.182 1.235±0.148 0.948±0.101 1.256±0.115 0.719±0.068* 
Spleen 0.620±0.046 0.407±0.077 1.016±0.193 1.153±0.237 0.466±0.109‡ 0.268±0.107 
Stomach 0.711±0.261 0.364±0.112 1.097±0.102 1.163±0.176 0.737±0.127 0.547±0.081 
Small intestine 0.985±0.142 0.755±0.140 0.975±0.148 1.241±0.151 0.970±0.133 0.738±0.087 
Large intestine 0.802±0.222 0.585±0.133 0.518±0.202 0.611±0.268 0.647±0.089 0.629±0.085 
 
Each data is mean ± SEM value (n = 6 rats/group). *p<0.05, **p<0.01 compared to respective control group. †††p<0.001 compared to 
respective control WKY group, ‡p<0.05, ‡‡‡p<0.001 compared to respective L-NAME treated WKY group. 
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 Table 5. Comparison of regional vascular resistance (mmHg/ml/min/gm) attained in various organs/tissues following either vehicle 
administration (saline, i.v. control group) or glycine (1.0 mmol/kg, i.v.) administration in 14 week old male WKY, L-NAME treated 
WKY and SHR strain. 
 
Tissue 
Regional vascular resistance (mm Hg/ml/min/gm) 
WKY Control 
     (Saline)  
 WKY Control 
     (Glycine)  
WKY(L-NAME) 
     (Saline)  
WKY(L-NAME) 
(Glycine)  
SHR 
(Saline)  
SHR 
(Glycine)  
Heart 41.42±3.305 16.35±3.5*** 48.43±6.5 119.81±22* 54.31±3.21† 87.50±3.99***‡ 
Left Kidney 32.77±2.39 11.07±3.9*** 42.03±2.6 103.11±13.5** 100.16±9.69†††11 224.45±15.7***‡ 
Right Kidney 33.14±4.14 11.04±1.2*** 43.21±3.4 105.02±11.3** 98.49±5.14††† 11 195.34±14.9***‡ 
Brain 128.31±6.3 39.05±11.3*** 100±8.2† 320.98±40.7*** 119.84±11.2 249.70±16.7***‡ 
Pancreas 102.65±18.9 54.28±14.2 225.39±19.3†† 928.57±15.6*** 203.33±15.4†† 292.07±18.9**‡‡‡ 
Diaphragm 604.16±34.4 296.87±30.9*** 233.72±19.1††† 805.30±16.4*** 551.20±15.311 726.64±23.5***‡ 
Skeletal muscle 106.91±24.8 55.15±6.5 141.32±12.4 145.60±30.1 145.7±15.3 292.07±14.9***‡‡ 
Spleen 187.09±18.5 186.73±24.6 254.83±16.1† 179.13±25.9 392.7±36.2†††1 453.51±38.3 
Stomach 163.38±16.1 208.79±15.2 222.22±22.5 156.49±28.9 248.3±40.23 383.91±61.3 
Small intestine 117.76±14.4 100.66±16.7 162.05±15.2 146.65±26.8 188.65±15.42†† 284.55±46.9 
Large intestine 114.63±14.9 129.91±12.6 305.01±33.5††† 297.87±31.4 282.84±35.85 333.86±17.4 
 
Each data point is mean ± SEM of 6 rats. *p<0.05, **p<0.01 and ***p<0.001 compared to vehicle treatment in the same group.  
†p<0.05 and ††p<0.01 compared to respective data of WKY group. ‡p<0.05, ‡‡ p<0.01, ‡‡‡ p<0.001, L-NAME vs. SHR group. 
¹p<0.05, ¹¹p<0.01 compared to L-NAME treated WKY group. 
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4.8. In vivo studies 
 
4.8.1. Acute hemodynamic effect of glycine in presence of NMDA blockers,  
MK-801/memantine 
Pooled data from several experiments revealed that, acute glycine (1.0 mmol/kg) 
administration evoked a fall in MAP in normotensive WKY rats (Figure 16). This fall in 
MAP (79 ± 7) was statistically significant (P < 0.05) compared to the baseline MAP (114 
± 6) in normotensive WKY rats (Figure 16). This decrease in MAP evoked by acute 
glycine administration was abolished by pretreatment with NMDA antagonist either MK-
801 (75 mg/kg) or memantine (50 mg/kg) in these group of rats (Figure 16). Conversely, 
in L-NAME treated hypertensive WKY rats, acute glycine (1.0 mmol/kg) administration 
evoked a significant increase (P < 0.05) in pressor response (180 ± 3 vs. 155 ± 4) 
compared to vehicle administration in the same group of rats (Figure17). This increase in 
MAP was attenuated and comparable to control value in presence of MK-801 (75 mg/kg) 
or memantine (50 mg/kg) in this group of hypertensive rats (Figure 17). In SHR strain 
glycine (1.0 mmol/kg) administration also evoked an increase in MAP (204 ± 5 vs. 177 ± 
8) compared to vehicle administration in the same group and this pressor response was 
abolished in the presence of the MK-801 (75 mg/kg) or memantine (50 mg/kg), when 
glycine was administered (Figure 18). From this data it is clearly evident that acute 
glycine administration evokes a depressor response in normotensive and a pressor 
response in hypertensive rat models and these responses were abolished when the rats 
were pretreatment with NMDA antagonist MK-801 or memantine. 
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4.8.2. Acute hemodynamic effect of glycine in presence of glycine transporter 
inhibitor, sarcosine 
Glycine (1.0 mmol/kg) evoked a fall in MAP that was increased further in the 
presence of sarcosine, a glycine transporter inhibitor in normotensive WKY rats (Figure 
16). Pretreatment with sarcosine (100 mg/kg) enhanced the fall in MAP significantly (P < 
0.05) compared to fall in MAP following glycine administration alone (64 ± 3 vs. 79 ± 7) 
in normotenive WKY rats (Figure 16). The glycine evoked fall in MAP in the absence of 
sarcosine was (79 ± 7 vs. 114 ± 6, P < 0.01), whereas in the presence of sarcosine this 
response was onefold higher (64 ± 3 vs. 114 ± 6, P < 0.001) compared to vehicle 
administration in normotensive WKY rats (Figure 16). Glycine (1.0 mmol/kg) evoked a 
pressor response (180 ± 3 vs. 155 ± 4, P < 0.05) compared to vehicle administration in 
the L-NAME pretreated WKY rats (Figure 17). This pressor response was increased 
further (215 ± 4 vs. 180 ± 3, P < 0.05) when glycine was administered in the presence of 
sarcosine (100 mg/kg) in this group of rats (Figure 17). Glycine administration in 
presense of sarcosine was significantly higher (215 ± 4 vs. 155 ± 4, P < 0.001) compared 
to vehicle administration (Figure 17). In the SHR strain, acute glycine administration 
increased the MAP (204 ± 5 vs. 177 ± 8, P < 0.05) compared to vehicle administration 
(Figure 18). When glycine was administered acutely in presence of sarcosine (100 
mg/kg), this pressor response was significantly elevated (P < 0.05) compared to (231 ± 4 
vs. 204 ± 5) glycine administration alone in the SHR strain (Figure 18). We also 
compared the acute glycine administration in presense of sarcosine (100 mg/kg) and the 
pressor response to glycine was found to be significantly higher (P < 0.01) compared to 
(231 ± 4 vs. 177 ± 8) vehicle administration in this group of rats (Figure 18). 
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Figure 16. The bar diagram compares the MAP (mmHg) following vehicle (saline, i.v. 
control) administration or acute glycine administration (1.0 mmol/kg, i.v), either in the 
presence or absence of sarcosine (100 mg/kg, i.p.) in 14 week old male WKY rats. This 
diagram also compares the MAP (mmHg) following vehicle (saline, i.v. control) 
administration and acute glycine administration after slow infusion of NMDA antagonist 
memantine (50 mg/kg, i.p.) and MK-801 (75 mg/kg, i.p) in 14 week old male WKY rats. 
Each bar represents mean ± SEM value (n = 6 rats).  
*p < 0.05, ***p < 0.001 compared to respective control. 
 †p < 0.05 compared to glycine treatment. 
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Figure 17. The bar diagram compares the MAP (mmHg) following vehicle (saline, i.v. 
control) administration or acute glycine administration (1.0 mmol/kg, i.v), either in the 
presence or absence of sarcosine (100 mg/kg, i.p.) in 14 week old male L-NAME treated 
(L-N) WKY rats. This diagram also compares the MAP (mmHg) following vehicle 
(saline, i.v. control) administration and acute glycine administration after slow infusion of 
NMDA antagonist memantine (50 mg/kg, i.p.) and MK-801 (75 mg/kg, i.p) in 14 week 
old male L-NAME treated WKY rats. Each bar represents mean ± SEM value (n = 6 
rats).  
*p < 0.05, ***p < 0.001 compared to respective control. 
 †p < 0.05 compared to glycine treatment. 
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Figure 18. The bar diagram compares the MAP (mmHg) following vehicle (saline, i.v. 
control) administration or acute glycine administration (1.0 mmol/kg, i.v), either in the 
presence or absence of sarcosine (100 mg/kg, i.p.) in 14 week old SHR strains. This 
diagram also compares the MAP (mmHg) following vehicle (saline, i.v. control) 
administration and acute glycine administration after slow infusion of NMDA antagonist 
memantine (50 mg/kg, i.p.) and MK-801 (75 mg/kg, i.p) in 14 week old SHR strains. 
Each bar represents mean ± SEM value (n = 6 rats).  
*p < 0.05, ***p < 0.001 compared to respective control. 
 †p < 0.05 compared to glycine treatment. 
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4.9. In vitro studies (using rat aortic rings) 
We conducted several experiments using thoracic aorta isolated from both 
normotensive WKY rats and SHR. Pooled data from these experiments revealed that 
glycine at different pharmacological concentrations evoked opposite responses in these 
normotensive and hypertensive rats. The results obtained from these in vitro studies were 
pretty consistent with our in vivo results. Glycine produced a vasodilator response in the 
aortic rings isolated from normotensive WKY rats (Figure 19). On the contrary glycine 
produced a contractile response in aortic rings isolated from SHR strain (Figure 22).   
 
4.9.1. Vasodilator response of glycine in normotensive WKY rats 
In phenylephrine (PE) constricted aortic rings glycine evoked (0.5 to 3.0 mmol/L) 
an endothelium and concentration-dependent vasodilatation (Figure 19). This vasodilator 
effect to glycine was abolished in endothelium denuded aortic ring preparation (Figure 
20). The response to glycine was found to be with much lower efficacy compare to the 
response elicited by ACh in the aortic rings isolated from normotensive WKY rats 
(Figure 21). The maximal response (Emax) to glycine was (40 ± 3 %) at 1.0 mmol/L and 
the effective median concentration (EC50) value calculated was (376.7 ± 158.7 μmol/L) in 
endothelium-intact aortic rings (Figure 20 and Figure 29).  
 
4.9.2. Vasoconstrictor response of glycine in SHR 
Glycine (0.5 to 3.0 mmol/L) evoked a dose dependent contractile response in PE 
constricted aortic rings isolated from SHR (Figure 22). This result supports our in vivo 
observations where glycine evoked an increase in MAP by increasing peripheral vascular 
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resistance and decreasing organ blood flow to several key organs/tissues (Table 3, Table 
4 and Table 5).  
 
4.9.3. Increase in basal tone by glycine in normotensive and hypertensive rat models 
We demonstrated the vascular effect of glycine in isolated aotic rings in absence 
of contractile agonist. Interestingly, glycine in the absence of PE increased the basal tone 
by increasing the basal preload tension (Max 1.4 g) in all aortic ring preparations from 
normotensive WKY rats as well as hypertensive SHR (Figure 23 and Figure 24). This 
increase in the basal tone was due to the activation of vascular NMDA receptors.  
 
4.9.4. Inhibition of glycine mediated response in the presence of either L-
NAME/MK-801 
Aortic rings preincubated with NMDA receptor antagonist MK-801 (10 μmol/L) 
for 30 minutes, completely inhibited glycine induced increase in basal tone in 
normotensive WKY rats and SHR strains (Figure 25, Figure 26 and Figure 27). In 
another set of experiments, pretreatment with L-NAME (100 μmol/L) for 30 minutes, 
abolished the vasodilator response to glycine in PE constricted aortic rings, isolated from 
normotensive WKY rats (Figure 28 and Figure 29). Increase in the basal tone evoked by 
glycine was compared with contractile agonists PE and potassium chloride (KCl). 
Although glycine, PE and KCl increased the basal tone in aortinc rings isolated from 
normotenive and hypertensive rats, pretreatment with NMDA antagonist MK-801 only 
inhibited the increased basal tone evoked by glycine but not to PE or KCl (Figure 26). 
Glycine evoked a dose dependent vasodilatation in aortic rings isolated from 
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normotensive WKY rats and this response was significantly inhibited when aortic rings 
are pretreated with NMDA antagonist MK-801 for 30 minutes (Figure 30 and Figure 31). 
In PE constricted aortic rings isolated from SHR produced a further contractile response 
to glycine and this was blocked by pretreatment with NMDA antagonist MK-801 (Figure 
32, Figure 33). Both the decrease and increase in MAP was blocked by pretreatment with 
NMDA antagonist MK-801 (Figure 8 A, B, C and Figure 12 A, B, C). Similarly, in aortic 
rings pretreated with NOS inhibitor L-NAME or in endothelium denuded preparation, we 
did not observe glycine mediated vasodilatation in these vessels isolated from 
normotensine WKY rats (Figure 20 and Figure 28). 
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Figure 19. A typical experiment that shows concentration dependent (0.1 to 3.0 mmol/L) 
vasodilatation evoked by in vitro addition of glycine (0.1 to 3.0 mmol/L) in (PE-1 
µmol/L) constricted endothelium-intact rat aortic rings isolated from a WKY rat. Similar 
responses were reproduced in 6 WKY rats (n = 6).    
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Figure 20. A typical experiment that demonstrates lack of a concentration dependent 
vasodilator response, to increasing concentrations of glycine (0.1 to 3.0 mmol/L), in PE 
(1 µmol/L) constricted (but endothelium-denuded) rat aortic rings isolated from WKY 
rat. Similar results were seen in 6 WKY rats (n = 6).  
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Figure 21. Comparison of vasodilator responses to ACh and glycine in endothelium-
intact PE (1 μmol/L) constricted rat aortic rings isolated from WKY rats. Each bar is a 
mean ± SEM value (n = 6).  
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Figure 22. A typical experiment that demonstrates the in vitro addition of glycine (0.1 to 
3.0 mmol/L), in a PE (1 μmol/L) constricted aortic ring isolated from SHR strain.  
 
 
 
 
 
 
 
 109 
 
 
 
0
1.0
2.0
Glycine (mmol/L)
0.1 0.5
1.0
Wash
2.0
● ●
●
●
●
3.0
WKY 
0 2 4 6 8 10
Te
ns
io
n 
(g
)
Time (min)
Control
 
Figure 23. A typical experiment that demonstrates the increase in basal vascular tone 
attained following cumulative addition of glycine (0.1 to 3.0 mmol/L) in vitro to rat aortic 
rings after its isolation from a 14 week old male WKY rats. Similar data were reproduced 
in 6 rats (n = 6). 
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Figure 24. A typical representative experiment that shows glycine (0.1 to 3.0 mmol/L) 
evokes  concentration-dependent (0.1 to 3.0 mmol/L) increase in basal tone in aortic rings 
isolated from SHR strain. This was seen in at least 8 rings isolated from 5 rats.  
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Figure 25. A typical experiment that demonstrates lack of  increased basal tone following 
addition of increasing concentrations of glycine (0.1 to 3.0 mmol/L) in rat aortic  rings  of 
WKY rat maintained in the presence of NMDA antagonist, MK-801 (10 µmol/L). This 
was seen in at least 8 rings isolated from 5 rats irrespective of whether the endothelium 
was present or absent.  
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Figure 26. The bar diagrams compare the maximal vasoconstrictor/tension responses 
generated by maximal concentrations of either glycine (3.0 mmol/L) or PE (3 µmol/L) or 
KCl (100 mmol/L) in WKY rat aortic rings with intact endothelium, in the presence and 
absence of NMDA antagonist MK-801 (10 µmol/L). Each data is mean  ± SEM value (n 
= 6). 
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Figure 27. A typical experiment that demonstrates lack of  increased basal tone following 
addition of increasing concentrations of glycine (0.1 to 3.0 mmol/L) in rat aortic  rings  of 
SHR maintained in the presence of NMDA  antagonist, MK-801 (10 µmol/L). This was 
seen in at least 8 rings isolated from 5 rats. 
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Figure 28. A typical experiment that demonstrates lack of vasodilator responses to 
glycine (0.1 to 3.0 mmol/L) in PE (1 µmol/L) constricted rat aortic rings in the presence 
of NOS inhibitor, L-NAME (100 µmol/L) in the incubated medium. 
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Figure 29. Concentration response curve compares the vasodilatation to glycine (0.1 to 
2.0 mmol/L) in presence and absence of NOS inhibitor L-NAME (100 μmol/L), in aortic 
rings isolated from normotensive WKY rat. 
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Figure 30. A typical experiment that demonstrates lack of vasodilatation to increasing 
concentrations of glycine (0.1 to 3.0 mmol/L) in PE (1 μmol/L) constricted rat aortic 
rings of WKY rats, when NMDA antagonist, MK-801 (10 μmol/L) is kept in the 
incubation medium.    
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Figure 31. Concentration response curves to glycine (0.1 to 2.0 mmol/L) determined in 
PE (1 μmol/L) constricted rat aortic rings with intact endothelium either in the presence 
of NMDA antagonist, MK-801 (10 μmol/L), or absence (control) of MK-801, maintained 
in the incubation medium. Each data pint is mean ± SEM value (n = 6 rats). 
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Figure 32. A typical experiment that shows glycine (0.1 to 3.0 mmol/L) evoked 
vasodilation is not present in PE (1 μmol/L) constricted SHR aortic ring, when NMDA 
antagonist, MK-801(10 μmol/L) is added in the incubation medium.  
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Figure 33. The bar diagram depicts the pooled mean ± SEM values (n = 6) for the 
maximal tension evoked by PE (1 μmol/L) alone and the maximal tension generated by 
the addition of glycine (3.0 mmol/L) in PE (1 μmol/L) constricted state, in the absence as 
well as presence of MK-801(10 μmol/L) in the aortic rings of SHR strain.  
 *p < 0.05 compared to respective control. 
 ††p < 0.01 compared to glycine treatment without MK-801. 
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CHAPTER 5. DISCUSSION 
 
5.1. Hypotensive effect of glycine in normotensive rats 
Acute administration of glycine (1 mmol/kg), a precursor/metabolite of L-serine, 
evoked a fall in MAP in normotensive WKY rats. Glycine acts as a coagonist in the 
NMDA receptors (Kasai et al., 1978). NMDA receptors are predominant in the central 
nervous system and their activation evokes cerebral vasodilatation (Faraci et al., 1993). 
There are studies showing the release of NO in central nervous system during the 
activation of NMDA receptors (Lin et al., 1999; Nagata et al., 1995).  However, studies 
have already reported the existence of NMDA receptors in the periphery (Crespi et al., 
2000; Slomowitz et al., 2002; Deng et al., 2002). Thus, using two NMDA antagonists the 
present study provides pharmacological evidence of NMDA receptor involvement in 
glycine evoked changes in BP. This suggests the presence of vascular NMDA receptors 
in the normotensive WKY rats. Glycine is transported into cells through selective amino 
acid transporter (Zafra et al., 1989; Hashimoto. 2006). Sarcosine, N-methyl glycine, at a 
dose of 100 mg/kg is known to inhibit the transport of glycine into cells and thus enhance 
the extracellular concentration of glycine (Yang et al., 2010). When extra cellular glycine 
level is enhanced by blocking glycine transporter, there is significant concentration of 
glycine available to interact with a limited population of all surface NMDA receptor 
present on selective renal vascular beds (Deng et el., 2002). Thus pretreatment with 
sarcosine inhibits transport of glycine and increases the availability of glycine to act on 
cell surface NMDA receptors to elicit a higher fall in MAP compared to treatment with 
glycine alone in normotensive WKY rats.  
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These findings confirm that the glycine mediated fall in MAP is in fact mediated via 
activation of vascular NMDA receptors. Recently, it has been suggested that glycine 
evoked fall in MAP was significantly attenuated in the presence of NOS inhibitor, L-
NAME (100 µmol/kg), in normotensive WKY rats (Mishra et al., 2008b). Taking these 
results together, the glycine evoked fall in MAP is due to activation of endothelial 
NMDA receptor which is linked to NO-mediated vasodilatation subsequent to Ca2+ 
induced NOS activation. 
 
5.2. Hypertensive effect of glycine in hypertensive rat models 
Both in L-NAME pretreated hypertensive WKY rats and SHR, paradoxically, 
glycine evoked increases in MAP, an effect that is opposite to what was observed in 
normotensive WKY rats. Pretreatment with NMDA antagonist, MK-801 (75 mg/kg), 
completely abolished the BP elevating effect of glycine in both hypertensive rat models. 
Again, pretreatment with memantine (50 mg/kg), another NMDA antagonist, also 
abolished the hypertensive effect of glycine. These results suggest NMDA receptors 
mediate the BP elevating effect of glycine following acute glycine administration. 
Glycine evoked elevation in MAP encountered in chronic L-NAME treated WKY and 
SHR strains were exaggerated further when the responses to glycine was determined 
following pretreatment with glycine transporter inhibitor, sarcosine.  
  
5.3. Comparison of glycine and L-serine effect in the regulation of BP  
It is important to discuss the changes in hemodynamic parameters following acute 
glycine and L-serine administration in the regulation of BP, since glycine serves as a 
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precursor/metabolite to L-serine (Greenstein et al., 1961). We have recently reported that 
L-serine, a non-essential amino acid derived from glycine promotes concentration and 
endothelium-dependent vasodilatation in rat mesenteric arterioles (Mishra et al., 2008a). 
In rat models, L-serine evokes a reversible, dose-dependent fall in MAP following acute 
intravenous administration without increasing HR; interestingly, both in vitro and in vivo 
effects of L-serine were more pronounced in NO compromised state (Jalil, 2008; Mishra 
et al., 2008a; Mishra et al., 2008b). The antihypertensive effect of L-serine likely 
involves the activation of endothelial calcium activated potassium (KCa) channels (Jalil. 
2008: Mishra et al., 2008a; Mishra et al., 2008b).  We have also demonstrated that L-
serine evoked fall in BP in rat models is primarily due to decrease in splanchnic vascular 
resistance which subsequently increases blood flow to splanchnic vascular beds (Mishra 
et al., 2010). Glycine, a precursor and metabolite of L-serine, also evoked a fall in BP in 
normotensive rats. Unlike serine, glycine administration exerts a pressor response in 
hypertensive rats. Both the depressor and pressor responses evoked by glycine are 
sensitive to blockade by NMDA antagonists (Mishra et al., 2008b). L-serine mediated 
vasodilator and hypotensive effect was abolished in the combined presence of  apamin 
and charybdotoxin but not NMDA antagonist. In contrast, glycine mediated changes in 
BP responses remain unaffected in the combined presence of apamin and charybdotoxin 
but the responses were abolished by NMDA antagonist (Mishra et al., 2008b). L-serine 
although derived from or metabolized to glycine, the vascular and BP responses to L-
serine and glycine are governed by different mechanisms and are not interlinked. It has 
already been reported that glycine is an inhibitory neurotransmitter and mediates its effect 
primarily by activating its receptors. Glycine receptors are prevalent in brain and spinal 
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cord. Activation of these receptors enhances chloride flux and subsequent 
hyperpolarization of cells (Imboden et al., 2001 and Lynch, 2004).  Glycine also acts as a 
co-agonist at NMDA glutaminergic receptors along with glutamate (Kasai et al., 1978 
and 1980). The existence of peripheral NMDA receptors in the kidney and heart has been 
previously demonstrated (Leung, 2002). Some reports suggest that acute glycine infusion 
increases blood flow and enhanced perfusion in the heart and kidney, via activation of 
NMDA receptors in these organs (Deng et al., 2002; Leung 2002). Data from the present 
thesis supports this notion and is consistent with the above findings. Glycine decreases 
MAP by reducing vascular resistance perhaps by increasing blood flow to heart, kidney 
and brain. This is primarily due to activation of NMDA receptors present in these organs 
since inclusion of NMDA receptor antagonists MK-801 as well as memantine inhibited 
these responses. This result confirms that the glycine evoked depressor response is 
mediated through activation of NMDA receptor and is consistent with the previous 
studies that reported glycine can act as a coagonist at NMDA receptor (Kasai et al., 
1978).  In hypertensive rats, glycine administration increases MAP by increasing vascular 
resistance in several organs that includes kidney, brain and heart by activating NMDA 
receptors since NMDA antagonists, MK-801, memantine attenuated the exaggerated 
pressor response to glycine noted in hypertensive rats. These two opposite responses to 
glycine suggest that in normotensive WKY rats, glycine activates endothelial as well as 
renal NMDA receptors that in turn increase intracellular Ca2+. This activates Ca2+ 
dependent NOS and subsequently results in increased NO production. Increase in NO 
activates the cGMP pathway that is likely responsible for vasodilatation in kidney, heart 
and brain vessels which reflects the fall in systemic vascular resistance (↓ TPR) and the 
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subsequent fall in MAP. In chronic L-NAME pretreated WKY rats, NOS is inhibited; 
therefore, glycine mediated activation of endothelial NMDA receptors does not 
contribute to increase NO generation. Activation of vascular NMDA receptor increases 
calcium influx which in turn increases contractility and contributes to increase in BP. In 
SHR, acute glycine administration also increases MAP by activating vascular NMDA 
receptors. It is well documented that in SHR strain NOS availability is diminished due to 
progressive endothelial dysfunction which contributes to arterial stiffness and loss of 
elasticity (Marque et al., 1999). Thus, both the depressor and pressor responses to glycine 
noted in normotensive and hypertensive rat models are mediated via activation of 
endothelial/vascular NMDA receptors respectively.  
 
5.4. Glycine induced changes in systemic and regional hemodynamic parameters  
 In normotensive WKY rats, acute glycine administration evoked a fall in MAP 
whereas in hypertensive L-NAME treated WKY rats and SHR, it evoked an increase in 
MAP. In WKY rats, acute administration of glycine decreased TPR and increased CO 
whereas in hypertensive rats, TPR increased and CO was decreased following glycine 
administration. In WKY rats acute glycine administration, increased blood flow to a 
significant extent to heart, kidney and brain whereas in hypertensive rats, blood flow was 
lower in heart, kidney, brain, pancreas, skeletal muscle and diaphragm. Changes in blood 
flow to the splanchnic region following glycine administration did not show any 
statistical significance in both normotensive and hypertensive rat models. Changes in 
vascular resistance in fact, drives the changes in blood flow. Pooled data from several 
experiments demonstrated that following glycine administration, peripheral organ 
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vascular resistance significantly decreases in heart, kidney and brain with subsequent 
increase in blood flow to these vital organs. This contributes to the fall in MAP in 
normotesive WKY rats. Conversely, glycine administration increases organ vascular 
resistance in heart, kidney, brain, pancreas, skeletal muscle and diaphragm in SHR and L-
NAME treated hypertensive WKY rats. This increase in organ vascular resistance in 
hypertensive rat models contribute to decrease in blood flow to these organs/tissues and 
results in an increase in TPR and MAP. Vascular resistance and blood flow are inversely 
proportional to each other and changes in these parameters contribute to the changes in 
blood flow and the accompanying changes in BP (Brunton et al., 2005). Again, acute 
administration of the NOS inhibitor, L-NAME, inhibits glycine mediated vasodilator and 
hypotensive responses in normotensive rats. On the contrary in hypertensive rat models, 
NOS is compromised. Therefore, glycine evokes vasoconstrictor and hypertensive 
responses. This study clearly explains the differential effects of glycine in normotensive 
and hypertensive rat models and both the effects are mediated by endothelial/vascular 
NMDA receptors.  
 
5.4.1. Glycine targets vital organs in rat models 
 Results of the present study demonstrate that unlike L-serine, glycine targets all 
the vital organs such as heart, kidneys, brain, pancreas, diaphragm and skeletal muscle in 
hypertensive rats. In normotensive rats glycine primarily targets heart, kidney and brain. 
Compared to glycine, L-serine targets predominantly the splanchnic vascular beds and 
decreases the splanchnic vacular resistance which contributes to the increase in 
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splanchnic blood flow and the subsequent decrease in TPR with reduction in BP in both 
normotensive and hypertensive rat models (Mishra et al., 2010).  
 
5.5. Proposed mechanism for glycine mediated vasodilatation 
 It is likely that NMDA receptors are expressed on EC and VSMC. The level of its 
expression could vary in different regional vascular beds. Accordingly, in aortic rings 
isolated from normotensive WKY rats, glycine via activation of NMDA receptor present 
on EC, promotes elevated [Ca2+]i and eNOS activity that results in NO-dependent 
vasodilatation. However, in NO compromised state such as in SHR strain, that exhibits 
endothelial dysfunction, NMDA receptor mediated vasodilatation is minimal or absent. 
Under such conditions, addition of glycine promotes NMDA-receptor mediated 
vasoconstriction via finite population of NMDA receptors present on VSMC. This may 
account for the vasoconstrictor responses to glycine observed in aortic rings isolated from 
SHR strain. This is also consistent with the elevated VSM tone seen under endothelium-
denuded states in normotensive WKY rats. Thus, glycine mediated increase in basal tone 
is due to the activation of a limited population of vascular NMDA receptors. In contrast, 
when experiments were performed to examine the effects of glycine in PE constricted 
vessels, it evoked concentration-dependent vasodilatation and this effect of glycine was 
abolished when L-NAME was present in the organ bath.  Thus, these data confirm that in 
aortic rings with intact endothelium, glycine promotes vasodilatation via releasing NO. 
Since inclusion of NOS inhibitor, L-NAME, inhibited glycine-mediated vasodilatation, 
activation of endothelial NMDA receptor is linked to NO mediated vasodilatation. It is 
reported that in the brain, NMDA receptor activation promotes NO production via 
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activation of nNOS and results in cerebral vasodilatation (Garthwaite et al., 1989; East et 
al., 1991; Faraci et al., 1993). It has also been reported that NMDA receptor functions as 
a membrane Ca2+ channel since activation of this receptor increases Ca2+ influx (Davis et 
al., 2003). Stimulation of Ca2+/Calmodulin dependent protein kinase signaling cascade by 
the activated NMDA receptor has been shown to regulate NO dependent axon and neurite 
outgrowth (Wayman et al., 2004). Although NMDA receptors are prevalent in the central 
nervous system and brain stem, their existance has also been reported in the peripheral 
vasculature (Crespi et al., 2000, Deng et al., 2002, Leung et al., 2002). Glycine is a co-
agonist at NMDA glutaminergic receptor (Kasai et al., 1978 and 1980; Danysz et al., 
1998). Glycine evokes its peripheral effect by binding to the vascular NMDA receptors 
and results in an increase in Ca2+ influx. This elevated Ca2+ probably activates eNOS 
present in the EC of the blood vessels. Activation of NOS produces NO in EC which 
diffuses to adjacent VSMC and causes cGMP dependent vasodilatation in normotensive 
rats. Our results from in vitro studies demonstrate that in endothelium denuded aortic ring 
preparartion glycine failed to evoke vasodilatation. Also in hypertensive rat models, 
glycine evokes a pressor response compared to depressor responses observed in 
normotensive rats. These responses are sensitive to NMDA antagonist. Results from our 
studies suggest that in the absence of endothelium, following denudation or in the 
presence of L-NAME, acute addition of glycine could activate only vascular NMDA 
receptors present on VSMC, elevate cytosolic free Ca2+ to enhance vascular tone. This 
results in increase in systemic vascular resistance and elevation in BP. Thus, our in vitro 
results are consistent with our in vivo observations. Acute glycine administration evoked 
a fall in BP in normotensive WKY rats with intact endothelium. Whereas, in L-NAME 
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pretreated hypertensive WKY rats, where endothelial function was compromised by 
inbition of NOS, glycine produced a pressor response via activation of NMDA receptors 
present on the VSMC. NO-dependent vasodilatation is limited or negligible in the 
established phase of hypertension in SHR strain (14 week old) due to progressive 
endothelial dysfunction (Zhou et al., 2008). In SHR strain, acute glycine administration 
increases BP via activation of NMDA receptors present on VSMC since NO availability 
is compromised due to endothelial dysfunction. A proposed mechanism that governs 
glycine evoked vasodilatation and fall in BP in normotensive rats and glycine evoked 
vasoconstriction and increase in BP in hypertensive rats are schematically reperesented 
(Figure 34).  
 
5.6. Proposed mechanism for glycine mediated vasoconstriction 
 In SHR strain, there is endothelial dysfunction and NMDA receptor activation 
following glycine administration, could not promote increased NO generation. Studies 
have already shown the existence of NMDA receptors in large conduit vessel such as 
aorta (Crespi et al., 2000). Thus, it is possible that in NO compromised state, glycine 
mediated activation of vacular NMDA receptor promotes intracellular Ca2+ influx and 
results in increased vascular tone. These in vitro results are consistent with our in vivo 
results where we have already demonstrated that acute glycine administration increases 
BP both in chronic L-NAME tereated WKY and SHR strains. Thus, acute single dose 
glycine administration activates endothelial NMDA receptors leading to enhance NO 
generation subsequent to Ca2+ dependent NOS activation and vasodilatation in blood 
vessels of critical organs such as kidneys, heart and brain. This contributes to a 
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significant fall in systemic vascular resistance and fall in MAP in normotensive rats. 
While a small population of NMDA receptor present on VSMC promotes increases in 
VSM basal tone. The dominant NO-mediated vasodilatation buffers enhanced vascular 
tone and causes fall in TPR and MAP. In contrast, in chronic L-NAME treated rats and 
SHR strains enhanced vascular tone in the absence of  NO generation (in L-NAME 
model) or compromised NO function (SHR model), induced by single administration of 
glycine predominates and contributes to its pressor response in hypertensive rat models. 
Previously, it was reported that glycine intake has potential to reduce BP by reducing 
oxidative stress and it is useful in normalization of blood glucose level (Martinez-
Abundis et al., 2003; Hafidi et al., 2006; Katayama et al., 2007). Glycine intake is 
suggested to be beneficial in the management of CNS related disorders (Buchanan et al., 
2007). However, our results suggest that acute glycine intake may be not beneficial in 
hypertensive subjects as suggested before since its acute administration is shown to evoke 
vasoconstriction and elevation of BP. In hypertensive rats, we demonstrate the possible 
mechanisms that contribute to the pressor response (Figure 34).   
 
 
 
 
 
 
 
 130 
  
Reversible
Activates endothelial 
SKCa and IKCa
Endothelium dependent
hyperpolarization
of VSMC
Vasodilatation
NMDA-R activation 
EC/VSMC
↑Ca2+ activates eNOS
and ↑NO 
↓TPR & ↓BP in both normotensive
and hypertensive rats
cGMP dependent 
vasodilatation
Vascular NMDA-R
mediated 
vasoconstriction
Normal 
endothelium
Endothelial 
Dysfunction
↓eNOS results ↓NO 
and ↑Ca2+
↓BP via NMDA-R 
on EC 
↑TPR & ↑BP via 
NMDA-R on VSMC 
Glycine L-serine
Normotensive Hypertensive
L-serine effect is not involved in 
response to acute glycine
administration
 
Figure 34. This schematic diagram compares the proposed mechanism of 
vasodilatation/fall in BP in normotensive rats and vasoconstriction/elevation in BP 
evoked by glycine in hypertensive rats. L-serine evokes only vasodilatation and fall in BP 
in all rat models. Note: Acute glycine responses shown in the present study is not 
mediated by its interconversion to L-serine. Glycine effects are mediated solely via 
activation of NMDA-receptors present on EC/VSMC.  
VSMC, vascular smooth muscle cell; EC, endothelial cell; NMDA, N-methyl D-
aspartate; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; cGMP, cyclic 3’, 5’ 
guanosine monophosphate; BP, blood pressure; SKca, calcium activated small 
conductance potassium channel; IKCa, calcium activated intermediate conductance 
potassium channel. 
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CHAPTER 6. CONCLUSIONS AND FUTURE WORK 
 
6.1. Summary of the present study 
 Glycine is not essential to diet since it can be formed in the body from other 
amino acids namely L-serine, L-alanine and L-threonine. Glycine is synthesized in liver 
of most vertebrates by glycine cleavage system which is also called glycine synthase and 
serine hydroxyl methyltransferase. This reaction is reversible and essential for cellular 
homeostasis. This reversible reaction of glycine to L-serine or L-serine to glycine is to 
maintain intracellular one carbon group which is essential for thymidine synthesis.  
Glycine and L-serine also plays an important role in purine and pyrimidine synthesis 
which are component of nucleotide base pairs. Other than that purines are part of ATP, 
GTP, cAMP biomolecules. Thus both glycine and L-serine are considered as conditional 
essential amino acids that are important for cellular growth and its survival. Glycine is 
well studied and considered as an inhibitory neurotransmitter in central nervous system. It 
also acts as a co-agonist at NMDA receptor along with D-serine. Glycine and its 
peripheral effect in vasculature are not well studied. So, this study focuses on the acute 
peripheral vascular effects of glycine. Although glycine and L-serine serves as a 
precursor/metabolite to each other, their mechanism of action is entirely different in 
normotensive and hypertensive rat models. Both Glycine and L-serine evoke their 
responses in an endothelium dependent manner. However, glycine mediated vasodilator 
effect is dependent on NO and endothelial NMDA receptor activation. NMDA receptor 
activation increases intracellular calcium which activates eNOS and contributes to NO 
synthesis. NO diffuses to adjacent VSMC and evokes vasodilatation via cGMP and PKG 
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mediated effects on VSMC. In contrast, L-serine mediated vasodilator responses are 
rather mediated via activation of endothelial SKCa and IKCa channels present on the 
endothelium. Activation of SKCa and IKCa channels hyperpolarizes adjacent VSMC. 
Thus, in normotensive rat models both glycine and L-serine evoke vasodilator responses 
and the mechanisms that contribute to the final response (vasodilatation/fall in BP) are 
entirely different. In contrast, L-serine evokes vasodilatation and a fall in BP in 
hypertensive rats but acute administration of glycine enhances vasoconstriction and 
elevates BP further in these rats. In hypertensive rat models endothelium-mediated/NO-
dependent vasodilator effect following endothelial NMDA receptor activation is 
significantly blunted due to endothelial dysfunction. Under such conditions, the vascular 
NMDA receptor (present on VSMC) mediated Ca2+ dependent vasoconstrictor effect 
predominants to elevate BP in hypertensive rat models. Glycine in hypertensive rat 
models evokes a contractile response since it activates NMDA receptor and increases 
intracellular calcium which increases vascular tone in absence of NO and subsequently 
contributes to increase in MAP. In summary the acute vascular response to glycine are 
not mediated by its bioconversion to L-serine. This information is new and provides 
useful insight for future studies. 
 
Thus, the results of this study demonstrate that glycine mediated responses are in fact due 
to activation of vascular NMDA receptors. The present study provides adequate new 
information to propose a long-term chronic study of glycine administration to ensure the 
beneficial effect of glycine that was reported earlier. Although a report suggested long 
term glycine intake induces formation of nitrosating agent in presence of NO, this 
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nitrosated compound may pose risk of gastrointestinal cancers (Cupid et al., 2004). 
Finally and most importantly we conclude that glycine mediated depressor/pressor 
responses are linked to NO generation or lack of NO in normotensive vs hypertensive 
states. Moreover, glycine administration affects blood flow to the critical organs such as, 
kidney, heart and brain. The present study also suggests that there are NMDA receptors 
could be expressed in vasculature and they may show differential responses between 
normotensive and hypertensive rats. This may assume significance following food intake 
with elevated plasma levels of glycine. So glycine could play an important role in 
cardiovascular disease states. 
 
6.2. Significance of the study 
 Following administration of acute bolus dose of L-serine or its 
precursor/metabolite glycine is accompanied by fall in BP in normotensive rats but 
glycine increases whereas L-serine decreases BP in hypertensive rat models (Mishra et 
al., 2008b). The present study demonstrates that glycine induced depressor and pressor 
response is mediated by vascular/endothelial NMDA receptor. Unlike L-serine, which 
targets splanchnic and small intestinal vascular beds, glycine a nonpolar amino acid, 
predominantly targets brain, heart and kidney but not the splanchnic vascular beds. 
Results of this study, infact, opens new avenues to study more precisely the beneficial 
effect of glycine intake in NO compromised state as several studies have suggested such 
possibilitis (Martinez-Abundis et al., 2003, Hafidi et al., 2006, Katayama et al., 2007 and 
Buchanan et al., 2007). It is possible that in long term glycine intake or treatement, 
glycine could be converted to L-serine. So the responses to glycine what we observed 
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following acute administration in the hypertensive rat models, could be different. But in 
hypertensive rat models, NO availability is still compromised and we know from the 
present in vitro, in vivo and regional hemodynamic studies that glycine effects are 
mediated following activation of vascular/endothelial NMDA receptors. In conclusion, it 
is to be noted that glycine induced changes in BP involve different vascular beds with 
completely different mechanisms compared to its metabolite/precursor L-serine.  
 
6.3. Future Work 
i. Long term chronic studies with glycine and L-serine administration are required to 
demonstrate whether over a period of time glycine is converted to L-serine. Their likely 
contribution to BP regulation following chronic treatment is currently unknown. It has to 
be addressed by studies in conscious rats using radiotelemetry methodology.  
ii. A detailed plan and robust studies to continue the acute in vitro effects of glycine on 
renal vascular beds and isolated renal arterioles obtained from normotensive and 
hypertensive rats are warranted since changes in maximal blood flow and vascular 
resistance occurred in this vascular bed. 
iii. It is also worth to study glycine responses in isolated coronary and cerebral blood 
vessels isolated from normotensive and hypertensive rats. 
iv. The demonstration of NMDA receptors either by receptor binding studies or glycine 
mediated changes in [Ca2+]i level in smooth muscle cells and rat aortic endothelial cells 
will add another new dimension.   
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